YouTube2Text

Elizabeth Holmes SEC Deposition AUG 23, 2017 3 OF 4 redacted — Transcript

by ANTL Media · 16,073 words · 3,046 segments · language en · Watch on YouTube

Full transcript

  1. 0:04We're back on the record at 1:17
  2. 0:07p.m. Ms. Holmes, did you have any
  3. 0:10substantive conversations with the SEC
  4. 0:11staff during the break?
  5. 0:13I did not.
  6. 0:14Thank you.
  7. 0:16Rupert Murdoch invested in the CT round
  8. 0:18of Theranos, correct?
  9. 0:20Yes.
  10. 0:20And he made his investment around
  11. 0:23January 2015?
  12. 0:26I had February in my mind, um but yes,
  13. 0:28around then.
  14. 0:30You were in discussions with him about
  15. 0:31investing in Theranos around November,
  16. 0:33December, and January, in that time
  17. 0:35frame?
  18. 0:36Yes.
  19. 0:38Did you review the binder of documents
  20. 0:41that Theranos sent to um Mr. Murdoch
  21. 0:44ahead of his his investment?
  22. 0:46I don't know that I reviewed it before
  23. 0:49he invested. I know I've seen it since
  24. 0:50then.
  25. 0:53Do you know who put the binder together?
  26. 0:54I don't.
  27. 0:57Do you know what Theranos
  28. 0:58who at Theranos would have had the
  29. 0:59responsibility to do something like that
  30. 1:00at the time?
  31. 1:01Uh again, similar to some of the other
  32. 1:04projects, we had different project
  33. 1:05managers who would compile materials
  34. 1:07before meetings or to follow up with
  35. 1:09people.
  36. 1:12Who would have instructed the project
  37. 1:13managers as to what to put into these
  38. 1:15binders for investors?
  39. 1:18I don't know that we gave binders to all
  40. 1:21investors. My memory is that after
  41. 1:24Rupert had said he wanted to invest,
  42. 1:26which was earlier,
  43. 1:28um we then said we would send him a
  44. 1:31a set of background materials on what we
  45. 1:33were trying to do.
  46. 1:36Okay, so you you might not have
  47. 1:38compiled and sent out binders to all
  48. 1:40investors or potential investors, but
  49. 1:42when you did, who would have been
  50. 1:45deciding what to include in these
  51. 1:46binders?
  52. 1:48Um again, I I don't think there was one
  53. 1:51person who was making decisions about
  54. 1:53this. I'm sure I had
  55. 1:55um discussions with the team about it.
  56. 1:57Sunny may have as well and
  57. 2:00people who were focusing on particular
  58. 2:02areas of the business that we want to
  59. 2:04share material on would have also.
  60. 2:07Besides you and Mr. Balwani, would there
  61. 2:10have been anyone else at Theranos who
  62. 2:11would have made decision a decision as
  63. 2:14to what to include or what to include in
  64. 2:15binders?
  65. 2:18Again, I I don't have memory of one of
  66. 2:20these specific interactions. My general
  67. 2:24memory is that
  68. 2:26whoever the subject matter
  69. 2:29point person was for a given area would
  70. 2:32aggregate materials for that area and
  71. 2:34that would be included.
  72. 2:35And who would have the final say as to
  73. 2:37what went into the binders or didn't go
  74. 2:38into the binders to investors?
  75. 2:41Again, I I don't know. I think it
  76. 2:43differed on a case-by-case basis. This
  77. 2:45was not a consistent practice across
  78. 2:48all the investors that we engaged with.
  79. 2:52Do you recall
  80. 2:54reviewing Mr. Murdoch's binder before
  81. 2:56you sent it to him?
  82. 2:57I do not.
  83. 2:59Do you recall sending binders to any
  84. 3:01other prospective investors other than
  85. 3:02Mr. Murdoch?
  86. 3:04No.
  87. 3:06Uh what about sort of the similar
  88. 3:08binders, the similar documents as what
  89. 3:10would be in a binder,
  90. 3:11just electronically, do you remember
  91. 3:12sending electronic documents to any
  92. 3:14potential investors?
  93. 3:15I don't have memory of it, no.
  94. 3:19Okay, if you would pick up exhibit 221
  95. 3:22again,
  96. 3:23which is this first document over here.
  97. 3:29You can turn to
  98. 3:32uh the page with page number ending
  99. 3:346306,
  100. 3:37which is page
  101. 3:3958
  102. 3:42of the document.
  103. 3:45358?
  104. 3:4758.
  105. 3:47Yep.
  106. 3:53Do you see there are some text messages
  107. 3:55here
  108. 3:56dated December 16th, 2014 to December
  109. 3:5917th, 2014. Are you on that page?
  110. 4:03I'm sorry, this is December 13th through
  111. 4:052015.
  112. 4:07Are you on page 58?
  113. 4:09Oh, I'm sorry, it's on 358.
  114. 4:10Okay, page 58.
  115. 4:12Yep.
  116. 4:22Okay.
  117. 4:27I mean, this doesn't look the same as
  118. 4:28mine.
  119. 4:32Are you sure you're on page 58?
  120. 4:3458 of everything.
  121. 4:36All right. Is this
  122. 4:38The date should be December 16th to
  123. 4:4017th, 2014.
  124. 4:46December 16th.
  125. 4:48What page number did you say it was?
  126. 4:506306.
  127. 4:526306. It's a difference.
  128. 4:57This could be a
  129. 4:59This is 68. Is it 68?
  130. 5:03My My copy looks like 58, but it's
  131. 5:05probably right. Do you see December 16th
  132. 5:07to 17th, 2014?
  133. 5:10Text messages? Okay.
  134. 5:12So, if you look halfway down the page,
  135. 5:14there's a text message from you to Mr.
  136. 5:17Balwani
  137. 5:19on December 16th, 2014 at 11:34 p.m. Do
  138. 5:24you see that?
  139. 5:25It says, "Are there any materials in the
  140. 5:27binders you think should be removed for
  141. 5:29Murdoch/News
  142. 5:31Corp?" Do you see that text message?
  143. 5:33I do.
  144. 5:35Are you asking Mr. Balwani for input as
  145. 5:37to what to include in the binder that
  146. 5:39you were going to provide to Mr.
  147. 5:40Murdoch?
  148. 5:43Again, I I don't remember the specific
  149. 5:44text, but reading it now, I I read it as
  150. 5:48asking for his advice on whether the
  151. 5:50right materials were in the Murdoch
  152. 5:51binder.
  153. 5:52So, what does this refresh your
  154. 5:54recollection that you would have
  155. 5:55reviewed Mr. Murdoch's binder before you
  156. 5:58sent it out?
  157. 5:59No, I don't have memory of doing that.
  158. 6:06Okay, you can put that one aside.
  159. 6:10Partner Fund Management, um did you
  160. 6:12understand that PFM was another way to
  161. 6:15um that Partner Fund Management was
  162. 6:17called? With the PFM Partner Fund
  163. 6:19Management are the same entity.
  164. 6:20I do.
  165. 6:21Okay.
  166. 6:22Uh PFM invested in the Series A round
  167. 6:24for Theranos, correct?
  168. 6:26Yes.
  169. 6:27How much did they invest?
  170. 6:30Uh I think it was 96 million.
  171. 6:32You were in discussions with PFM in late
  172. 6:342014 and January 2000 I'm sorry, late
  173. 6:38I'm sorry, over again. You were in
  174. 6:39discussions with PFM in late 2013 and
  175. 6:41January 2014 regarding their potential
  176. 6:44investment.
  177. 6:45Uh as I was saying,
  178. 6:47I met them in December of '14 and we had
  179. 6:49a meeting to discuss their potential
  180. 6:51investment in January of I'm sorry,
  181. 6:53December of '13 and met them
  182. 6:55for the first time, and then in January
  183. 6:57of '14 we had a meeting to discuss their
  184. 6:58potential investment.
  185. 7:00Do you remember having a series of
  186. 7:01meetings with them in January 2014
  187. 7:03before their investment?
  188. 7:05Um as far as I know, there's only one
  189. 7:07that that I was in. Um I I understand
  190. 7:09there were other interactions also.
  191. 7:11Which meeting was that?
  192. 7:13Um meeting which they came to
  193. 7:17discuss
  194. 7:18Theranos and our vision and whether
  195. 7:21get an understanding of whether
  196. 7:23uh it would be the right investment
  197. 7:24opportunity.
  198. 7:25Did you present any materials to PFM at
  199. 7:27that meeting?
  200. 7:29I don't recall.
  201. 7:31What do you recall telling them about
  202. 7:33Theranos?
  203. 7:34I I don't recall the discussion very
  204. 7:37well. I've seen notes uh of those
  205. 7:39meetings since then.
  206. 7:40What Whose notes have you seen?
  207. 7:42Um
  208. 7:43notes that were
  209. 7:46um
  210. 7:47taken I think by members of PFM's team.
  211. 7:51Which members of PFM's team?
  212. 7:53I don't know.
  213. 7:54How did you review those notes?
  214. 7:56Um with counsel in preparing for
  215. 7:59potential litigation with PFM.
  216. 8:01Did you review the notes anytime prior
  217. 8:03to reviewing them with counsel?
  218. 8:05No.
  219. 8:08Do Do you remember who from PFM you met
  220. 8:10with in that meeting?
  221. 8:11Um
  222. 8:12some sort of subsequent meeting at
  223. 8:14Theranos that you attended?
  224. 8:15Um I I believe he was there as well as
  225. 8:18members of his team
  226. 8:20um that were doing due diligence. I I
  227. 8:22don't know um what their names were by
  228. 8:24memory sitting here now.
  229. 8:27Before that meeting with uh with him, do
  230. 8:28you remember being introduced to him in
  231. 8:31December time frame?
  232. 8:32I do.
  233. 8:32Uh
  234. 8:33were you introduced to anyone else from
  235. 8:34PFM?
  236. 8:35I think it was in the first meeting.
  237. 8:37Did Do you Do you recall whether he was
  238. 8:38at that second meeting?
  239. 8:39I don't.
  240. 8:43Uh who was at that meeting from
  241. 8:45Theranos?
  242. 8:47Uh which meeting?
  243. 8:48The meeting that you were talking about
  244. 8:50where you met with PFM and talked about
  245. 8:52the vision for the company.
  246. 8:53In January?
  247. 8:54In January.
  248. 8:55Um
  249. 8:56at least myself and Sunny. I don't know
  250. 8:58if anyone else was in the meeting.
  251. 9:04I'm going to hand to you what's been
  252. 9:06previously marked Theranos exhibit 255.
  253. 9:14Is there a copy?
  254. 9:18Exhibit 255 purports to be
  255. 9:22Um and actually I also had a view
  256. 9:24exhibit 256 I think.
  257. 9:26Uh both the email and the attachment
  258. 9:28were marked separately as exhibits.
  259. 9:31Um
  260. 9:32exhibit 255 purports to be
  261. 9:34a January 17th, 2014 email from Sunny
  262. 9:38Balwani to subject re
  263. 9:40with Bates number THPFM0003870572.
  264. 9:48And exhibit 256
  265. 9:51purports to be a
  266. 9:53PowerPoint presentation with title
  267. 9:56Theranos with starting Bates number
  268. 9:58TS-0315637.
  269. 10:02Have you seen exhibit 255
  270. 10:07uh before?
  271. 10:09I don't think so.
  272. 10:10Have you seen exhibit 256 before?
  273. 10:14Um
  274. 10:16I don't know. It looks like an internal
  275. 10:19Theranos deck.
  276. 10:25Um
  277. 10:26So, if you turn back to exhibit 255,
  278. 10:38Is it all part of one
  279. 10:40doc- or maybe it's just two different
  280. 10:41types of paper.
  281. 10:43I think it might have been printed on
  282. 10:44two different types of paper because we
  283. 10:45ran out of paper.
  284. 10:47Okay.
  285. 10:47But, it is one one document.
  286. 10:49I understand that. Okay.
  287. 10:50Um
  288. 10:51If you turn back to exhibit 255,
  289. 10:54Mhm.
  290. 10:55um you'll see there's
  291. 10:59an email
  292. 11:01on 573, which is the second page of
  293. 11:04exhibit 255,
  294. 11:06from and to Sunny Balwani.
  295. 11:09And he says, "Sunny, thanks again for
  296. 11:11the time you spent with our team walking
  297. 11:12us through the Theranos story. It's
  298. 11:14amazing to see what you and Elizabeth
  299. 11:16and the rest of the Theranos team have
  300. 11:17accomplished over the last 10 years."
  301. 11:22Was the initial meeting between you, Mr.
  302. 11:25Balwani, and the PFM team around January
  303. 11:2710th, 2014?
  304. 11:29I think so.
  305. 11:30Would he have been referring to that
  306. 11:31meeting with you and Mr. Balwani?
  307. 11:35I don't know. I mean, I could
  308. 11:37infer that from looking at this email
  309. 11:39right now, but I don't know.
  310. 11:45Okay, and if you turn um
  311. 11:48to exhibit 256, then you'll see that
  312. 11:52and actually, if looking back at exhibit
  313. 11:54255, you'll see that Mr. Balwani is
  314. 11:56sending a uh presentation to
  315. 11:59Um he says, "Attached, please find a PDF
  316. 12:01which is a very confidential slide deck
  317. 12:03of discussions we had."
  318. 12:06You see that?
  319. 12:07Mhm.
  320. 12:07And then he is attaching a very long
  321. 12:09presentation, which is at exhibit 256.
  322. 12:14Do you remember presenting this
  323. 12:15presentation to and the rest of the PFM
  324. 12:19team at that January 2014 meeting?
  325. 12:22I don't think we presented it.
  326. 12:24And what do you What do you recall
  327. 12:26presenting?
  328. 12:28Uh my memory is that we did not present
  329. 12:29slides. We had a discussion.
  330. 12:33So, your testimony is that you remember
  331. 12:34not presenting slides, but having a
  332. 12:36discussion?
  333. 12:37Yes, and I think there may have been one
  334. 12:39slide that was pulled up, which resulted
  335. 12:42in a request for the deck, but I don't
  336. 12:43think we
  337. 12:44did a presentation to a slide deck. I
  338. 12:46think we We may have used a slide in
  339. 12:48support of a discussion point.
  340. 12:50Which slide uh do you recall using
  341. 12:53during that meeting?
  342. 12:53I I don't know. I don't remember it.
  343. 12:56So, you recall a slide um being the
  344. 12:59impetus for PFM requesting the slide
  345. 13:02deck, but you don't remember what that
  346. 13:03slide was.
  347. 13:04Yes.
  348. 13:07So, looking through the presentation
  349. 13:15you said that this looks like some kind
  350. 13:17of internal uh Theranos presentation. Do
  351. 13:20you recall that this testimony?
  352. 13:23Um
  353. 13:24who would have prepared this slide deck?
  354. 13:28I I don't think it was one person. I
  355. 13:29think it was an aggregation of content
  356. 13:32from different areas of the company that
  357. 13:34we just kept on adding to over time.
  358. 13:37Were you involved in preparing any part
  359. 13:38of this presentation?
  360. 13:41I I don't know. I I haven't gone through
  361. 13:43the whole thing. I'm just flipping
  362. 13:45through it. It looks like it's
  363. 13:47it's a lot of content about different
  364. 13:49parts of our company.
  365. 13:52Was Mr. Balwani involved in preparing
  366. 13:55parts of this presentation?
  367. 13:56I don't know.
  368. 14:01Uh just generally during that January
  369. 14:032014 meeting with PFM, were there parts
  370. 14:06that you
  371. 14:07discussed with PFM versus parts that uh
  372. 14:11Mr. Balwani discussed with them?
  373. 14:13And what are what are some of the topics
  374. 14:16uh you recall discussing with PFM versus
  375. 14:18what Mr. Balwani discussed?
  376. 14:20So, I I don't have recollection of
  377. 14:22specific conversations in the meeting. I
  378. 14:24know in general in these initial
  379. 14:26meetings with investors, I would talk
  380. 14:28about our vision and what we were trying
  381. 14:29to do as a company.
  382. 14:32What did you recall Mr. Balwani talking
  383. 14:34about?
  384. 14:35Again, I I don't have specific
  385. 14:36recollection of of what we said in the
  386. 14:38meeting.
  387. 14:40As a as a general matter, would he have
  388. 14:41a role in in certain topics more
  389. 14:44prominently?
  390. 14:45Yes, I'm on the operations of the
  391. 14:47business and on the models or
  392. 14:51projections that we were putting
  393. 14:52together.
  394. 14:54Okay, so I just want to draw your
  395. 14:55attention to a couple of the slides in
  396. 14:57this presentation. So, if you turn to
  397. 14:59644.
  398. 15:20This slide is titled media. Do you see
  399. 15:23that? And the third bullet point was was
  400. 15:25I correct in that?
  401. 15:26Yes.
  402. 15:27And the third bullet point down it says
  403. 15:29not disclosing device, work with
  404. 15:32hospitals and or the DOD or future
  405. 15:35innovations or expansion plans.
  406. 15:37Do you recall ever
  407. 15:39um
  408. 15:40putting together slides or documents
  409. 15:42with that statement?
  410. 15:44No.
  411. 15:45Do you know do you have any
  412. 15:46understanding as to what this is talking
  413. 15:47about?
  414. 15:49Sitting here now, I read it to mean that
  415. 15:52we were not disclosing to the media uh
  416. 15:56essentially the the plan for the mini
  417. 15:58lab uh
  418. 16:00work with hospitals or other future
  419. 16:02innovations or expansion plans.
  420. 16:04Did you have that same understanding in
  421. 16:06January 2014?
  422. 16:07I don't know.
  423. 16:14Would you turn to page 651?
  424. 16:24So, here there's a slide
  425. 16:26titled same test, a whole new approach.
  426. 16:29And the first line says Theranos runs
  427. 16:31any test available in central
  428. 16:33laboratories and processes all sample
  429. 16:35types.
  430. 16:37Was this statement true in January 2014?
  431. 16:42I I believe so. I don't know
  432. 16:46how much of our infrastructure had been
  433. 16:48operationalized in January, but
  434. 16:50essentially the concept that you could
  435. 16:52collect any type of sample and through
  436. 16:54Theranos have it processed
  437. 16:57um was certainly the business model.
  438. 17:01Uh was it true that Theranos was could
  439. 17:03run any uh or was running any test
  440. 17:06available in central laboratories?
  441. 17:10Theranos as a lab service offering, I I
  442. 17:12believe so because we had I think at
  443. 17:14that point reference labs set up to
  444. 17:16process some of the samples.
  445. 17:18So, you see there's some pictures above
  446. 17:20that statement with
  447. 17:22what looks like
  448. 17:24a collection device. Is that part of the
  449. 17:26Nanotainer
  450. 17:28or the capillary tube?
  451. 17:30Yes.
  452. 17:30That is the Nanotainer.
  453. 17:32Uh were you worried at all that this
  454. 17:36might create an impression that Theranos
  455. 17:38was using its um
  456. 17:41only its
  457. 17:43uh manufactured devices to run tests?
  458. 17:47Uh my
  459. 17:49general recollection is the point we
  460. 17:50were trying to make here is that you
  461. 17:52could do collection through finger stick
  462. 17:54and have an end-to-end lab service
  463. 17:57offering and that was the discussion
  464. 17:59that would accompany
  465. 18:01this type of slide.
  466. 18:02Okay.
  467. 18:03But when you when you say that was the
  468. 18:04discussion that would accompany it, do
  469. 18:05you recall
  470. 18:07accompanying the slide with that
  471. 18:09discussion you just described?
  472. 18:10I I I don't I don't have specific
  473. 18:12recollection of discussing this slide um
  474. 18:15but just sitting here now reading it um
  475. 18:19and knowing how we would generally
  476. 18:21describe what we were trying to do um
  477. 18:23that's my read on it.
  478. 18:26Okay, but you don't recall providing
  479. 18:28that sort of
  480. 18:29commentary in connection with this slide
  481. 18:30anyway.
  482. 18:31I I don't think that these slides were
  483. 18:33discussed with PFM.
  484. 18:35What what about any other investor?
  485. 18:37I don't think so.
  486. 18:38So so I guess to
  487. 18:40answer my question, you didn't you don't
  488. 18:42recall providing that sort of commentary
  489. 18:44that you just described
  490. 18:45um
  491. 18:46in connection with this slide with any
  492. 18:48in potential investor in Theranos.
  493. 18:50I I do not. I actually think this may
  494. 18:52have been on our website in the context
  495. 18:55of making that point, but I'm I'm not
  496. 18:57sure.
  497. 19:00Was the statement true in January 2014
  498. 19:04that Theranos was running any test
  499. 19:06available in central laboratories using
  500. 19:08one of your finger stick methods?
  501. 19:11I I don't think that's what this I I
  502. 19:13think the point that we were trying to
  503. 19:15make here is that you could collect
  504. 19:16finger stick for some tests and then
  505. 19:18also through Theranos as a lab service
  506. 19:20provider, we could accommodate any
  507. 19:22sample and do any tests so people
  508. 19:23wouldn't have to go to two different
  509. 19:26locations.
  510. 19:27So you're saying that the pictures at
  511. 19:28the top and the statement below it are
  512. 19:30actually two separate statements?
  513. 19:32I believe so.
  514. 19:33What what about the statement at the
  515. 19:34very top? Same tests, a whole new
  516. 19:36approach.
  517. 19:38Uh
  518. 19:39what was Theranos providing a whole new
  519. 19:41approach with respect to
  520. 19:43um
  521. 19:44running any test available in a central
  522. 19:45laboratory?
  523. 19:48Again, my my read on this sitting here
  524. 19:50now is that the the point we were trying
  525. 19:51to make was that we were introducing
  526. 19:53this finger stick methodology for blood
  527. 19:56testing
  528. 19:58more broadly and you could run any test
  529. 20:01available in in a central or through
  530. 20:03Theranos as a lab provider
  531. 20:05in a central lab.
  532. 20:07So So with the I I guess my question is
  533. 20:10just with Theranos as a central lab
  534. 20:11provider, was it was
  535. 20:14as a central lab provider, was it
  536. 20:15offering a whole new approach?
  537. 20:18We believed so because we were the first
  538. 20:20to introduce finger stick, the first to
  539. 20:22do upfront eligibility telling people
  540. 20:26how much they were going to owe, the
  541. 20:27first to create this consumer experience
  542. 20:28and we were trying to offer the ability
  543. 20:31to run any test through our laboratory
  544. 20:33when patients came into retail.
  545. 20:43You turned to 667.
  546. 20:47I said 57.
  547. 20:49667.
  548. 20:55You'll see there's a slide here with the
  549. 20:56title commercial.
  550. 20:58And
  551. 20:59the first line under that says key
  552. 21:01deployments and then there are a number
  553. 21:03of bullet points two which are emergency
  554. 21:06rooms, hospitals, and provider offices.
  555. 21:08And the second bullet point underneath
  556. 21:09is DoD.
  557. 21:11Do you see that?
  558. 21:12Yes.
  559. 21:13Was Theranos's technology deployed
  560. 21:16in emergency rooms, hospitals, and
  561. 21:18provider offices?
  562. 21:20No.
  563. 21:22Was Theranos's technology deployed at
  564. 21:25the DoD?
  565. 21:27I I believe the burn study was underway
  566. 21:29at multiple hospitals at this time, but
  567. 21:31not otherwise.
  568. 21:33Is that what you would have been talking
  569. 21:34about on this slide?
  570. 21:37No, sitting here now, my read on this is
  571. 21:39that this is our aspiration for what we
  572. 21:42thought all the key deployments would be
  573. 21:43in building out a commercial
  574. 21:45infrastructure.
  575. 21:46Was that your understanding at the time,
  576. 21:47too, that these were aspirational?
  577. 21:50I Again, I don't remember
  578. 21:53this specific slide, but yes, there's a
  579. 21:55lot of aspirational content in this deck
  580. 21:57of
  581. 21:58what we were trying to do with the
  582. 22:00company.
  583. 22:01And And I guess how
  584. 22:03how can you distinguish between what was
  585. 22:04aspirational at the time and what
  586. 22:06Theranos was actually doing at the time
  587. 22:07when we're when reviewing this slide
  588. 22:08deck?
  589. 22:10I I don't think these slides were
  590. 22:12intended to be stand-alone. They were
  591. 22:14a whole set of content that we would
  592. 22:17share as background material that were
  593. 22:19intended to be supplement with
  594. 22:20discussion and interaction.
  595. 22:23Okay, so do you Do you Do you recall
  596. 22:25ever providing that supplemental
  597. 22:26discussion and interaction with any
  598. 22:28potential investors?
  599. 22:29I'm
  600. 22:31I I know that we had multiple follow-on
  601. 22:34meetings in which investors would ask
  602. 22:36questions about
  603. 22:37areas of the business that they were
  604. 22:40interested in. I don't know that
  605. 22:41investors actually ever read this deck
  606. 22:43and and
  607. 22:48I guess
  608. 22:49just back my back to my question, do you
  609. 22:50recall ever having that sort of
  610. 22:52discussion about this deck with any
  611. 22:54investors? Like whether whether this
  612. 22:56whole thing or or a subset of it.
  613. 22:58I don't believe an investor ever asked a
  614. 23:00question about the deck that I know of.
  615. 23:04Did you ever provide a subset of this
  616. 23:06presentation to any potential investors?
  617. 23:09I don't know.
  618. 23:11Would it surprise me if you did?
  619. 23:14Not necessarily. I I don't have memory
  620. 23:16of doing that. Um
  621. 23:19If you were providing um to the extent
  622. 23:21that you did provide
  623. 23:23uh a subset of this presentation to any
  624. 23:25potential investors, how would that
  625. 23:27potential investor know
  626. 23:29what was aspirational versus what was
  627. 23:32actually the truth at the time that
  628. 23:35they were
  629. 23:36reviewing the presentation?
  630. 23:38In general, my understanding is that
  631. 23:40these materials were sent after we had
  632. 23:42meetings with
  633. 23:45investors or potential investors or
  634. 23:47partners and they followed discussions
  635. 23:49about what we were trying to do, who we
  636. 23:51were as a company,
  637. 23:53um and were intended as background
  638. 23:55material on
  639. 23:57exactly what we were trying to do.
  640. 24:01Turn to 682
  641. 24:04and 683.
  642. 24:06Can I just ask a quick question?
  643. 24:07Yes, sure.
  644. 24:08So, this one's in your in these meetings
  645. 24:10that you had with investors and
  646. 24:12potential investors,
  647. 24:15did you talk about what was aspirational
  648. 24:18at what you wanted to achieve?
  649. 24:21Yes.
  650. 24:22And did you talk about specifically the
  651. 24:23technology
  652. 24:25and blood draw and what was in place at
  653. 24:27that time versus what was aspirational?
  654. 24:29Was there a clear delineation between
  655. 24:31those two?
  656. 24:33We tried to do that. Looking back on it
  657. 24:36now and especially in the case of PFM, I
  658. 24:39wish we had done that even more
  659. 24:41explicitly including in writing. We
  660. 24:42didn't have the same type of systems in
  661. 24:44place we have now on things like sending
  662. 24:46out materials, but we thought we had at
  663. 24:48the time.
  664. 24:49And what specifically do you wish you
  665. 24:51would have communicated to PFM at the
  666. 24:53time?
  667. 24:55What I I I think we did communicate,
  668. 24:57which is phase one, phase two, um what
  669. 25:01we were doing in phase one, what the
  670. 25:02business model was, what technology we
  671. 25:04were using, and what we were doing in
  672. 25:07phase two, and what technology we were
  673. 25:09intending to use in phase two.
  674. 25:11I I know that we also really thought we
  675. 25:13were closer to phase two than we were.
  676. 25:17J- I just want to make sure I'm
  677. 25:18understanding. So, you Is it your
  678. 25:19testimony that you did communicate phase
  679. 25:21one and phase two to PFM, or you wish
  680. 25:23you would have conveyed phase one and
  681. 25:25phase two to PFM?
  682. 25:26It's my testimony that I think I did. We
  683. 25:28We did. Theranos did. I I don't know if
  684. 25:30it was me specifically. And it's also my
  685. 25:33testimony that, you know, I I understand
  686. 25:35if you take this document in isolation,
  687. 25:38um that
  688. 25:39we could have done a much better job in
  689. 25:42creating documents that we were sending
  690. 25:43to people. We We didn't intend these
  691. 25:46documents to be stand-alone, and and you
  692. 25:49know, sitting here now, I know we could
  693. 25:50have been much better at the way we
  694. 25:52prepared materials and shared them, um
  695. 25:55than we were at the time.
  696. 25:57So, is it your testimony that in the
  697. 25:58discussions, the meetings that you had
  698. 26:00with PFM, that you did describe phase
  699. 26:04one and phase two, but that that's not
  700. 26:06was what was That was not necessarily
  701. 26:08reflected here in the document that
  702. 26:09we're looking at.
  703. 26:10Y-
  704. 26:11Yes, it's my testimony that I believe in
  705. 26:14the meetings that we had with PFM, we
  706. 26:15did describe phase one and phase two.
  707. 26:18A- And additionally, in looking at the
  708. 26:20slide deck, I don't think this slide
  709. 26:22deck does a good job of describing that
  710. 26:24on a stand-alone basis.
  711. 26:27Okay. Thank you. Who Who bears
  712. 26:28responsibility for the failures of this
  713. 26:30plan deck?
  714. 26:32I I- It's my understanding that PFM
  715. 26:34understood, based on what we at least
  716. 26:37tried to communicate, um
  717. 26:40or or I guess I I I had thought that we
  718. 26:42had communicated, um
  719. 26:44that this was an internal deck that we
  720. 26:47were sharing with them for background
  721. 26:48purposes, not that
  722. 26:50it was intended to operate as a
  723. 26:52standalone document. And um
  724. 26:56I I wish we had done a much better job
  725. 26:57of, you know, documenting that in terms
  726. 27:00of the communication with them, but we
  727. 27:02had at least intended to be clear when
  728. 27:03we sent it that this was
  729. 27:05supposed to be an internal sort of
  730. 27:07compilation of materials that we were
  731. 27:09sharing for background purposes.
  732. 27:12Sure, I understand that, but I guess you
  733. 27:13know, I think you described it as you
  734. 27:15you um
  735. 27:16you know, you sort of wish it had it it
  736. 27:18had it it had been communicated in a
  737. 27:19different way.
  738. 27:20Yep.
  739. 27:21Um
  740. 27:22whose responsibility would it have been
  741. 27:23to communicate in a different way to PFM
  742. 27:26at that time?
  743. 27:29Um
  744. 27:32well, I I mean, in retrospect, I I think
  745. 27:34we should have in writing documented
  746. 27:37what I think we had said to them, which
  747. 27:39was that this was a compilation of
  748. 27:40internal materials that we would share
  749. 27:43and exactly what what the deck was. I
  750. 27:45I think we we at least attempted to
  751. 27:47communicate that verbally, um but we
  752. 27:50don't have good record of that.
  753. 27:52Well, who's the we in that sentence, I
  754. 27:54guess? Is it Is it you and Sunny? Is it
  755. 27:55Is it Theranos the company? Who?
  756. 27:57Theranos the company. I I can't remember
  757. 27:59the specifics of the conversations with
  758. 28:01PFM and
  759. 28:02um
  760. 28:03you know,
  761. 28:04the moment when they they asked for the
  762. 28:06deck. I I just know my general
  763. 28:08understanding of what happened in the
  764. 28:10context of sending this material.
  765. 28:12Okay, so can you point to anyone who
  766. 28:14would be who who you think bears
  767. 28:16responsibility for uh
  768. 28:19for the way in which this deck was sent
  769. 28:20and communicated to PFM to PFM?
  770. 28:24Um
  771. 28:25well, I
  772. 28:26I mean,
  773. 28:27Theranos, myself, Sunny in the context
  774. 28:30of the engagement
  775. 28:32with PFM. We were the principals
  776. 28:34interacting with them.
  777. 28:35Okay, so
  778. 28:36um
  779. 28:37I I I mean, I'm assuming that Theranos
  780. 28:38is an entity and you and Sunny are
  781. 28:40individuals. Other than you and Sunny,
  782. 28:42are there any other individuals you feel
  783. 28:43that bear responsibility for that?
  784. 28:46For what?
  785. 28:47For for for um
  786. 28:49you know as you said sort of the the the
  787. 28:51way in which the slide deck was
  788. 28:52communicated to PFM.
  789. 28:56Um
  790. 28:57I don't I don't know if anybody else had
  791. 28:59had an interaction with them around it
  792. 29:00and this was
  793. 29:02the way the company was operating at at
  794. 29:04this time generally and
  795. 29:06we believed at that time that the people
  796. 29:08who we were interacting with understood
  797. 29:09what the content we were sharing was.
  798. 29:17If you turn to um 682 and 683 and I
  799. 29:20think you're on 682 right now.
  800. 29:23We're also looking at uh 683. We're also
  801. 29:25looking at 682 as well. What were you
  802. 29:28trying to convey in these two pages?
  803. 29:32Have you Have you seen these slides
  804. 29:34before?
  805. 29:36Whether it's outside of this
  806. 29:37presentation
  807. 29:38or not.
  808. 29:40Um
  809. 29:43I have. I I remember them as being from
  810. 29:45the slide deck we were using with our
  811. 29:47retail partners to talk about what the
  812. 29:50process would be at retail for doing a
  813. 29:52finger stick.
  814. 29:54So here are you trying to convey that
  815. 29:57where it says lab today on 682,
  816. 30:00uh are you trying to convey that you
  817. 30:02know today blood testing is being done
  818. 30:04via
  819. 30:06venipuncture using a syringe?
  820. 30:09Is that
  821. 30:10what you're trying to convey by the
  822. 30:11first picture?
  823. 30:12I don't know. I I think in general these
  824. 30:15were slides describing finger stick at
  825. 30:18retail.
  826. 30:22Okay. Um so what what is the message
  827. 30:25that you're portraying by 6 um 3682?
  828. 30:29Do you want to take a minute to look at
  829. 30:31the slides before and after?
  830. 30:33Sure.
  831. 30:53Sitting here now, my read is that it's a
  832. 30:54description of what finger stick testing
  833. 30:56would be like
  834. 30:58at Walgreens.
  835. 31:01Is that is that meaning aspirationally?
  836. 31:04I I mean, my memory is that most of this
  837. 31:07deck is aspirational.
  838. 31:09But yeah, this is I mean, it starts with
  839. 31:11a
  840. 31:12sort of Walgreens store and then the
  841. 31:14process of doing the collection and what
  842. 31:17that process would be like and I
  843. 31:19again think these slides were from
  844. 31:21actually a retail deck on what the
  845. 31:24service offering would be.
  846. 31:27So, turning to 685,
  847. 31:32there's a slide titled New Possibilities
  848. 31:35in Lab and it says
  849. 31:37under routine, specialty, and esoteric
  850. 31:40testing,
  851. 31:41all 1,000 plus currently run tests, CPT
  852. 31:44codes are available through Theranos.
  853. 31:47And again, Theranos runs any test
  854. 31:48available in central laboratories.
  855. 31:51Was that a true statement in January
  856. 31:532014 that all 1,000 plus currently run
  857. 31:56tests or CPT codes are available through
  858. 31:58Theranos?
  859. 32:01Again, I think it's the same comment
  860. 32:03that the whole range of tests could be
  861. 32:04run through Theranos' lab and I I think
  862. 32:07that was true in January 14, but
  863. 32:10I'm not sure how much of that had been
  864. 32:11operationalized in January 14 cuz we'd
  865. 32:14only been open for a couple months at
  866. 32:16that point.
  867. 32:17And so, this would have been including
  868. 32:19tests being run on the modified
  869. 32:20commercially available machines, tests
  870. 32:22being run on the unmodified commercially
  871. 32:24available machines, and also tests being
  872. 32:26sent out to reference labs.
  873. 32:27That's right.
  874. 32:30Was that conveyed to potential investors
  875. 32:32when you were talking about how 1,000
  876. 32:35plus currently run tests were being
  877. 32:37offered through Theranos Labs.
  878. 32:40I don't know if that we were ever
  879. 32:42talking specifically about this. Um I I
  880. 32:45thought that we had and talked about
  881. 32:48what we were running and that we were
  882. 32:50including reference lab capabilities in
  883. 32:53our service offering in phase one.
  884. 32:55When you say you thought you had
  885. 32:56conveyed that, do you know that you
  886. 32:58conveyed it to any potential investors?
  887. 33:00Again, I don't remember specific
  888. 33:02conversations on on these points.
  889. 33:05Okay, going to 698 then.
  890. 33:22There's a slide here titled validation
  891. 33:24of Theranos.
  892. 33:26And at the bottom of the slide it says
  893. 33:28excerpts from Johns Hopkins due
  894. 33:30diligence and technology validation. Do
  895. 33:32you see that?
  896. 33:33Yes.
  897. 33:35Did Johns Hopkins conduct a validation
  898. 33:37of Theranos' technology?
  899. 33:41Um
  900. 33:42as I understand it, they did for
  901. 33:44Walgreens.
  902. 33:46What do you mean as you understand it
  903. 33:48they did for Walgreens?
  904. 33:50Um Walgreens team would talk about the
  905. 33:52Johns Hopkins validation meaning that
  906. 33:54Johns Hopkins had signed off on
  907. 33:57um
  908. 33:58sort of the architecture of the
  909. 34:00technology as a platform that could do
  910. 34:02all these things.
  911. 34:06Earlier in your testimony, you testified
  912. 34:08that no devices were ever given to Johns
  913. 34:10Hopkins. Do you remember that?
  914. 34:13We brought one to the meeting, I
  915. 34:15believe. Um but yes, I don't think
  916. 34:17Theranos independently shipped devices
  917. 34:19to Hopkins.
  918. 34:20Okay, so how did Johns Hopkins conduct a
  919. 34:23validation of your technology if it
  920. 34:24didn't have access to your your device?
  921. 34:27Again, my understanding is that this was
  922. 34:29really looking at the design and
  923. 34:30architecture of the technology, would it
  924. 34:33be capable of doing something that no
  925. 34:35other point-of-care technology had ever
  926. 34:38been able to do?
  927. 34:40You also testified earlier that your
  928. 34:42understanding of validation included
  929. 34:43such factors as linearity and precision
  930. 34:46and test specificity. Do you remember
  931. 34:48that?
  932. 34:49The assay or chemistry validation, yes.
  933. 34:51Okay. Do you remember Johns Hopkins
  934. 34:53doing any of that?
  935. 34:55Uh study on your on of your either your
  936. 34:57test or your devices?
  937. 34:59No.
  938. 35:00Wait. Wait. Wait.
  939. 35:01That you any of the assays you mean as
  940. 35:03opposed to the device?
  941. 35:05So, I'm asking her, do you under do you
  942. 35:08remember Johns Hopkins doing any
  943. 35:11um
  944. 35:12work on either validating the test or
  945. 35:16the devices under that framework, what
  946. 35:19we just talked about? Looking at
  947. 35:21linearity, precision, test specificity.
  948. 35:24They reviewed some of that data, um they
  949. 35:26did not perform validations themselves.
  950. 35:29They just reviewed data.
  951. 35:32Okay, turn to 700.
  952. 35:36Can I ask another question on
  953. 35:38698? Do you see the line above that it
  954. 35:40says
  955. 35:41Theranos' lab infrastructure is
  956. 35:43validated under FDA, ICH, and World
  957. 35:46Health Organization guidelines?
  958. 35:48Mhm.
  959. 35:49Uh
  960. 35:50was that a true statement as of January
  961. 35:512014?
  962. 35:56I don't know.
  963. 35:57Um
  964. 35:58I I know that our understanding of the
  965. 36:01standards that we were using to validate
  966. 36:03our LDTs, our lab-developed tests,
  967. 36:05changed over time. And I think this is
  968. 36:07what that is referring to, but
  969. 36:10um we later
  970. 36:12learned that we should be using
  971. 36:13different standards.
  972. 36:15All right. What what what do you take
  973. 36:16lab infrastructure to mean?
  974. 36:20I I'm not sure. I don't know.
  975. 36:23I I I could guess. Yes or no?
  976. 36:27Uh I mean
  977. 36:28Is it Is is is the is the sentence here
  978. 36:32Theranos' lab infrastructure
  979. 36:34is validated under FDA, I C H, and World
  980. 36:36Health
  981. 36:37World World Health Organization
  982. 36:39guidelines?
  983. 36:40Um a statement that
  984. 36:42Theranos' TSPU has been validated under
  985. 36:44these guidelines?
  986. 36:47No. I I'm sitting here now, my read is
  987. 36:49that it's
  988. 36:50talking about the standards that we were
  989. 36:53using for validation of the
  990. 36:54lab-developed tests.
  991. 36:56I get all right.
  992. 36:57Were lab-developed tests often called
  993. 36:59infrastructure?
  994. 37:01I don't know.
  995. 37:02Did you ever use that word to call
  996. 37:04in referring to lab-developed tests?
  997. 37:06I I don't know.
  998. 37:08Can you recall an instance where it was?
  999. 37:10I can't.
  1000. 37:13Who drafted that slide?
  1001. 37:16I don't know.
  1002. 37:17I think it again, like one of these
  1003. 37:18slides, it's it's an old slide that was
  1004. 37:21carried through in a lot of decks or
  1005. 37:23and/or updated over time.
  1006. 37:26If you turn to 700,
  1007. 37:30there's a slide titled products.
  1008. 37:32Mhm.
  1009. 37:33And here under devices, there's a bullet
  1010. 37:35point that says mini lab and 4S for
  1011. 37:37automated processing. Do you see that?
  1012. 37:40Yes.
  1013. 37:41These weren't the only devices that were
  1014. 37:43used by Theranos for patient testing,
  1015. 37:45were they?
  1016. 37:47I I don't think either of them were used
  1017. 37:48for patient testing.
  1018. 37:50Okay. What Why didn't you include, for
  1019. 37:51instance, 3.5? That was being used for
  1020. 37:54patient testing.
  1021. 37:56I
  1022. 37:56I believe that this is a specific slide
  1023. 37:59talking about what products the company
  1024. 38:01wanted to develop on a go-forward basis.
  1025. 38:04And
  1026. 38:05what's your basis for that belief?
  1027. 38:07I I generally recognize it, and I
  1028. 38:11generally have memory that we were
  1029. 38:12trying to distinguish sort of products
  1030. 38:14from the clinical lab, that Theranos was
  1031. 38:16developing products, and it also was
  1032. 38:18operating a lab, and that this part of
  1033. 38:20the discussion was on the the technology
  1034. 38:22or the products that we were trying to
  1035. 38:23build.
  1036. 38:30Do you Did you ever talk to investors
  1037. 38:33and show them this particular slide?
  1038. 38:36Again, I I don't remember ever having
  1039. 38:38conversations with investors about the
  1040. 38:40slide deck.
  1041. 38:42Did you But did you ever have any
  1042. 38:44conversations with investors about this
  1043. 38:46particular slide?
  1044. 38:47I don't think so.
  1045. 38:48What about 701, which is the next page?
  1046. 38:52There are pictures
  1047. 38:55of a number of things under the title
  1048. 38:58overview of Theranos systems.
  1049. 39:01Under Theranos analyzers is there's a
  1050. 39:03picture of two analyzers there. What are
  1051. 39:05these pictures of?
  1052. 39:08Um one is of the the 3-series device. I
  1053. 39:11don't know if it's a 3.0 or 3.5, and the
  1054. 39:13other one is one of the 4-series devices
  1055. 39:16in mini labs.
  1056. 39:17Okay, so here under you know, you're
  1057. 39:20you're actually showing pictures of
  1058. 39:22Theranos analyzers. Why didn't you
  1059. 39:23include other machines that you were
  1060. 39:25using, including the commercially
  1061. 39:27available machines here?
  1062. 39:29Again, I don't think this part of the
  1063. 39:31presentation, these slides, were used to
  1064. 39:33support anything about the clinical lab.
  1065. 39:35I think this was talking about the
  1066. 39:36proprietary technologies that we were
  1067. 39:38working to develop
  1068. 39:39for distributed testing.
  1069. 39:41Did you think that this might give the
  1070. 39:43wrong impression that the only Theranos
  1071. 39:45analyzers Theranos was using were its
  1072. 39:47own proprietary devices, and that
  1073. 39:49Theranos wasn't using commercially
  1074. 39:50available machines to conduct testing?
  1075. 39:52Not at the time, cuz we weren't using
  1076. 39:54these decks. Um
  1077. 39:58for the purpose of trying to provide a
  1078. 40:00comprehensive overview of the company.
  1079. 40:02Um but again, were I preparing this
  1080. 40:04content now, we're we're being very
  1081. 40:06careful to prepare this content very
  1082. 40:07differently now.
  1083. 40:11So do you think it could have been made
  1084. 40:12clearer that you were not providing an
  1085. 40:14overall uh of what the company was doing
  1086. 40:18or using and that
  1087. 40:20uh you could have been more specific as
  1088. 40:22to the analyzers Theranos was using at
  1089. 40:24the time.
  1090. 40:26At the time we did not think that these
  1091. 40:28slides were
  1092. 40:30ever going to be looked at as
  1093. 40:32stand-alone descriptions of what we were
  1094. 40:34doing. We thought they were
  1095. 40:36um
  1096. 40:37tools to facilitate different parts of
  1097. 40:39the discussion.
  1098. 40:41Now again, we are taking a very
  1099. 40:43different approach to how we're
  1100. 40:45preparing any content.
  1101. 40:47Why don't you turn to 733?
  1102. 40:49Sorry, before we leave the slide again,
  1103. 40:50just the the slide is titled overview of
  1104. 40:53Theranos systems.
  1105. 40:54Mhm.
  1106. 40:55So sorry, is that a yes?
  1107. 40:56Yes.
  1108. 40:57Uh i- i- i-
  1109. 40:58I mean is it your basic testimony that
  1110. 41:00this isn't an overview of Theranos
  1111. 41:01systems, it's a overview of Theranos's
  1112. 41:04planned systems?
  1113. 41:06Um Theranos systems was the word that we
  1114. 41:09generally used to describe the
  1115. 41:11proprietary family of technologies that
  1116. 41:13we were developing with many lab. And
  1117. 41:16yes, it's my general memory that this
  1118. 41:19this deck was about was aspirational. So
  1119. 41:22these were the technologies we wanted to
  1120. 41:23take into the FDA and distribute on the
  1121. 41:27market, but obviously had not done that
  1122. 41:29yet.
  1123. 41:31Just one other follow-up Mr. Holmes. Um
  1124. 41:33you just said prior to Mr. uh Cole had
  1125. 41:36asked question that the deck was a tool
  1126. 41:39to facilitate discussion.
  1127. 41:41Yeah.
  1128. 41:41Um so I know you said that you didn't go
  1129. 41:43over the deck or other than that one
  1130. 41:45slide.
  1131. 41:47Did you have the deck there in the
  1132. 41:48meeting and you were going through it
  1133. 41:50with PFM or how did that work?
  1134. 41:53Um
  1135. 41:55I I don't know that we had the deck with
  1136. 41:56us. Um it's my general understanding
  1137. 41:59that we did not go through a deck with
  1138. 42:01PFM at all. I think that on a computer,
  1139. 42:03I don't know if it was mine or
  1140. 42:05in fact I'm probably was not mine cuz I
  1141. 42:07generally didn't bring computers to
  1142. 42:08meetings, but a slide was put up to
  1143. 42:11support a conversation and I generally
  1144. 42:14understand that after that PFM asked,
  1145. 42:16"Could you send the deck that slide is
  1146. 42:18from?" And we sent this big deck.
  1147. 42:22So, when you were having the discussions
  1148. 42:24with PFM employees, did
  1149. 42:27did you have the deck in front of you
  1150. 42:30even though you weren't projecting it or
  1151. 42:31any of the slides from it? Did you have
  1152. 42:34it as kind of a tool that you would use,
  1153. 42:36either you or Mr. Balwani would use to
  1154. 42:39facilitate the discussion that you
  1155. 42:40previously testified to?
  1156. 42:41I I don't think it was up on the screen.
  1157. 42:44Um I think it was literally brought up
  1158. 42:45with a slide to facilitate discussion. I
  1159. 42:48I
  1160. 42:49can infer from that that it was on a
  1161. 42:51computer that was in the room uh at the
  1162. 42:53time of the meeting.
  1163. 42:54Okay.
  1164. 42:55I guess
  1165. 42:56Did you Did you have a copy for your of
  1166. 42:58the slide deck for yourself to use as
  1167. 42:59sort of a
  1168. 43:00set of talking points?
  1169. 43:01No.
  1170. 43:02Did you generally have a prepared set of
  1171. 43:03talking points when meeting with
  1172. 43:05investors?
  1173. 43:06No.
  1174. 43:07What did you use to sort of guide the
  1175. 43:09discussion?
  1176. 43:10Um
  1177. 43:12I I I would generally speak um in in
  1178. 43:15free form because the part of the
  1179. 43:17conversation that I had was was our
  1180. 43:18vision. So, it was about talking about
  1181. 43:20who we were, what we were trying to do,
  1182. 43:22and then I would talk about
  1183. 43:24the inventions. And then from there um
  1184. 43:28there was generally follow-on
  1185. 43:29discussions where people would do
  1186. 43:30diligence and I for the most part was
  1187. 43:32not involved in those uh next set of
  1188. 43:34conversations.
  1189. 43:36Because they were with Mr. Balwani or
  1190. 43:38someone else from Theranos?
  1191. 43:39Yes.
  1192. 43:40Just
  1193. 43:41if if you didn't use the deck during the
  1194. 43:44meeting and you didn't use it yourself
  1195. 43:47as a tool to facilitate the discussion,
  1196. 43:49then my question would be, what then is
  1197. 43:50the point of the deck?
  1198. 43:53The The deck was a
  1199. 43:55um
  1200. 43:56amalgamation of slides
  1201. 43:58that Theranos had. It was used by
  1202. 44:00different teams, different people for
  1203. 44:02different purposes. It's It's literally
  1204. 44:05a set of marketing content, a set of
  1205. 44:06content from the website, a set of
  1206. 44:08content about the labs, a set of content
  1207. 44:10about our retail relationships, you
  1208. 44:12know, data, and it was a working tool
  1209. 44:15that different people throughout the
  1210. 44:16company would use if they needed to pull
  1211. 44:19a piece of information to support a
  1212. 44:21discussion. So, if they wanted, for
  1213. 44:23example, a picture of the system if they
  1214. 44:25were trying to describe the system, they
  1215. 44:27would pull that slide from the deck to
  1216. 44:29support discussion.
  1217. 44:30So, your testimony as I understand it is
  1218. 44:34you had this deck already in place and
  1219. 44:37there was a discussion during the
  1220. 44:38meeting with PFM in which you pulled out
  1221. 44:41one slide, projected that, and then PFM
  1222. 44:43from that point said, "Hey, can we get
  1223. 44:45later on said, can we get a copy of the
  1224. 44:46deck that you used?"
  1225. 44:47Yes.
  1226. 44:48Okay.
  1227. 44:50Who pulled up that slide?
  1228. 44:52I don't know.
  1229. 44:53It wasn't Mr. Balwani?
  1230. 44:56I again, I don't know. I I know that I
  1231. 44:58generally didn't bring computers to
  1232. 44:59meetings, so probably, but I don't
  1233. 45:01remember it specifically.
  1234. 45:03Okay. If you go to page 733,
  1235. 45:08there's a slide titled clinical data
  1236. 45:11and then a whole section full of slides
  1237. 45:14behind it.
  1238. 45:16Yes.
  1239. 45:17You see that?
  1240. 45:22And let's just take a look at a specific
  1241. 45:26slide.
  1242. 45:27754.
  1243. 45:36Looks like there's a chart for ferritin.
  1244. 45:39Do you see that?
  1245. 45:40Yes.
  1246. 45:41What is this chart
  1247. 45:44supposed to convey?
  1248. 45:47Um data that we thought was
  1249. 45:49representative
  1250. 45:50as to the performance of the the
  1251. 45:52chemistry
  1252. 45:54that was
  1253. 45:56designed to be able to handle small
  1254. 45:57sample volumes.
  1255. 46:00Okay, so so take me through what's being
  1256. 46:03compared here. So,
  1257. 46:05is this a correlation graph?
  1258. 46:08Uh it's a method comparison graph.
  1259. 46:10A method comparison graph. So, what are
  1260. 46:11you comparing here?
  1261. 46:14You're comparing the Theranos assay to
  1262. 46:16one by Elpco
  1263. 46:18uh
  1264. 46:20uh
  1265. 46:20diagnostics, I think is their name.
  1266. 46:22And what are each of these assays being
  1267. 46:25tested on? What What device or platform
  1268. 46:28are they being tested on?
  1269. 46:30Um I believe ferritin was on the
  1270. 46:32Theranos TSPU, and the Elpco is on a
  1271. 46:35kit.
  1272. 46:37Okay, and the kit, is that What is that?
  1273. 46:39Is that like a manual kit?
  1274. 46:43I I think so. I don't know for sure.
  1275. 46:45Okay, so you're comparing the
  1276. 46:47performance of the Theranos assay on the
  1277. 46:49TSPU versus um
  1278. 46:52a reference assay using
  1279. 46:55some other platform. Is that fair?
  1280. 46:57Yes.
  1281. 46:58Okay. And so is this trying to show that
  1282. 47:00the Theranos method is quite close to
  1283. 47:03the reference method?
  1284. 47:06It's showing what the concordance is. At
  1285. 47:08the time, we thought this was really
  1286. 47:10good. Uh today, we actually wouldn't
  1287. 47:13accept this as being as good as we we
  1288. 47:15thought it was.
  1289. 47:17Why do you say that?
  1290. 47:20Um
  1291. 47:21we we used to believe that cutoffs like
  1292. 47:24R squared and about this many samples
  1293. 47:26were sufficient to show validation of a
  1294. 47:29test. And we have much more
  1295. 47:31comprehensive uh mechanisms in place
  1296. 47:33right now for the standards to which
  1297. 47:35we're validating.
  1298. 47:36Okay.
  1299. 47:37And so you understood in January 2014
  1300. 47:40though that ferritin wasn't actually
  1301. 47:42being tested on the TSPU in patient
  1302. 47:44testing, though, correct?
  1303. 47:47I don't know that I understood that in
  1304. 47:49January 2014. Um I I knew there was a
  1305. 47:52limited number of tests on the TSPU in
  1306. 47:54the in the
  1307. 47:55Would it surprise you if you knew that
  1308. 47:57ferritin was being tested instead on a
  1309. 47:59commercially available machine at that
  1310. 48:01time?
  1311. 48:02I I don't think I would have known that.
  1312. 48:04Um but it wouldn't surprise me if it was
  1313. 48:06being tested on a commercial machine.
  1314. 48:08Do you think that the fact that you're
  1315. 48:09including these correlation graphs that
  1316. 48:12compare the Theranos methods to
  1317. 48:14reference methods and Theranos methods
  1318. 48:17being on the TSPU would uh create the
  1319. 48:20impression to people who were reviewing
  1320. 48:23these slides that Theranos was using its
  1321. 48:25TSPU for all of these tests at that
  1322. 48:28time?
  1323. 48:29Why?
  1324. 48:30Um because these data were intended to
  1325. 48:33reflect the fact that we had worked on a
  1326. 48:36large number of chemistries
  1327. 48:38to
  1328. 48:39um handle small sample volumes and that
  1329. 48:41we would work to bring those up in the
  1330. 48:43lab over time. This was not intended to
  1331. 48:45reflect the clinical lab.
  1332. 48:47This This is all under a section called
  1333. 48:48clinical data.
  1334. 48:49Yes.
  1335. 48:50right? I get Can you just differentiate
  1336. 48:52between in your mind difference between
  1337. 48:54clinical lab and clinical data?
  1338. 48:57I I believe clinical data is the term to
  1339. 48:59reflect plots when you're using actual
  1340. 49:02clinical samples for the plot as opposed
  1341. 49:04to some of the experiments that you were
  1342. 49:06referencing earlier, which are not done
  1343. 49:08on on actual live samples. They're done
  1344. 49:10on
  1345. 49:11um
  1346. 49:13derived materials. Um
  1347. 49:15this part of the discussion
  1348. 49:17um was broadly about the the assays that
  1349. 49:20we were developing to the extent that we
  1350. 49:22showed this data.
  1351. 49:25So are you saying that patient samples
  1352. 49:27were being used uh in order to do this
  1353. 49:30method comparison?
  1354. 49:32Yes.
  1355. 49:33So So like leftover material from a
  1356. 49:36uh from a test run on a on a traditional
  1357. 49:38machine could be used in to
  1358. 49:41to test a Theranos assay. Is that right?
  1359. 49:43So the the last part of an assay sort of
  1360. 49:47validation process, as I understand it,
  1361. 49:49is the method comparison and that's
  1362. 49:51where you take an actual sample and
  1363. 49:54compare it to methods. The rest of the
  1364. 49:56steps like linearity or precision are
  1365. 49:59not done with actual patient samples.
  1366. 50:02And that's why it says clinical data.
  1367. 50:04This is the that last step where you're
  1368. 50:05actually doing the comparison with the
  1369. 50:07clinical sample.
  1370. 50:10All right, we'll take a short break. Uh
  1371. 50:12we're off the record at 2:06 p.m.
  1372. 50:22We're back on the record at 2:20 p.m.
  1373. 50:25Ms. Holmes, did you have any substantive
  1374. 50:26conversations with the SEC staff during
  1375. 50:28the break?
  1376. 50:29I did not.
  1377. 50:31Did you
  1378. 50:32ever send a subset of the
  1379. 50:36internal slide deck something similar to
  1380. 50:38exhibit 256 to
  1381. 50:41I don't know.
  1382. 50:44Would it surprise you if you did?
  1383. 50:46No.
  1384. 50:48Why not?
  1385. 50:50The
  1386. 50:50it was a the tool that we used uh
  1387. 50:53in supporting discussions.
  1388. 50:57But you had earlier said that uh
  1389. 51:00you wouldn't provide the slides without
  1390. 51:02some explanation
  1391. 51:04about the slides.
  1392. 51:05No, I'm I'm sorry, what I was trying to
  1393. 51:07say
  1394. 51:07I don't think that's what she said but
  1395. 51:08please continue.
  1396. 51:09Yeah, I what I was trying to say was
  1397. 51:10that the the slides were
  1398. 51:13um
  1399. 51:14not created to be standalone material.
  1400. 51:19Okay, so what were they created for?
  1401. 51:22They were created to support
  1402. 51:23discussions.
  1403. 51:25Okay, I don't know how that's any
  1404. 51:26different from what I just asked you.
  1405. 51:29I'm sorry, maybe I misunderstood the
  1406. 51:31question.
  1407. 51:31I had understood you to say that the
  1408. 51:34slide deck wasn't meant to be sent to
  1409. 51:37other
  1410. 51:38other people such as potential investors
  1411. 51:40without an explanation for those slides.
  1412. 51:44Isn't of wasn't that the testimony.
  1413. 51:46I'm maybe I
  1414. 51:49didn't communicate clearly. I What I was
  1415. 51:51attempting to communicate is that I'm
  1416. 51:54when those slides were created, they
  1417. 51:56were not created to operate in a
  1418. 51:59standalone way.
  1419. 52:01We would share them
  1420. 52:03and generally with people with whom we
  1421. 52:05were in active discussion.
  1422. 52:08Do you recall sending materials more
  1423. 52:10generally with with the connected day
  1424. 52:12exhibit 256 or otherwise?
  1425. 52:15I I I recall that he was advising
  1426. 52:18me
  1427. 52:19and us in the early days of my
  1428. 52:21relationship with him. He
  1429. 52:23even acted as my counsel for a period of
  1430. 52:25time.
  1431. 52:27So we we shared a lot of information
  1432. 52:28with him.
  1433. 52:30Did you share any information with him
  1434. 52:31in connection with obtaining potential
  1435. 52:34investments in Theranos?
  1436. 52:36I'm we shared information with him in
  1437. 52:39the context of the C2 round and the
  1438. 52:41people who
  1439. 52:43we were
  1440. 52:44I'm talking to and I remember asking for
  1441. 52:47his advice on you know, what information
  1442. 52:49would make sense to to share.
  1443. 52:54The
  1444. 52:58I guess is it your testimony that you
  1445. 53:00retained to provide you with legal
  1446. 53:01advice on that issue?
  1447. 53:04I'm
  1448. 53:05I I'm I'm just trying to be careful
  1449. 53:06about how
  1450. 53:07Yeah, I was
  1451. 53:08as Holmes' lawyer
  1452. 53:10for a significant amount of time
  1453. 53:12on a number of issues.
  1454. 53:14And
  1455. 53:16we then are talking about whether this
  1456. 53:17goes into it or not. Let Let us have one
  1457. 53:19one second. There's a lot of stuff that
  1458. 53:21was clearly attorney-client privilege.
  1459. 53:23We're off the record at 2:23 p.m.
  1460. 53:26Yeah, just have really good
  1461. 53:27conversation.
  1462. 53:31We're on the record at 2:33 p.m. Ms.
  1463. 53:33Holmes, did you have any substantive
  1464. 53:35conversations with the SEC staff during
  1465. 53:37the break?
  1466. 53:37No.
  1467. 53:38So just to follow up on a question,
  1468. 53:40did you understand Did you have an
  1469. 53:42understanding in 2014 that certain
  1470. 53:45materials were provided in connection
  1471. 53:47with his potential investment in
  1472. 53:48Theranos?
  1473. 53:49Yes or no.
  1474. 53:50Uh um
  1475. 53:52If you can answer yes or no.
  1476. 53:54I I I understood that they were
  1477. 53:56generally being provided for advice
  1478. 53:58um in connection with the C2 round that
  1479. 54:01we were um
  1480. 54:03that we were working toward.
  1481. 54:05What materials were those?
  1482. 54:07I don't remember specifically. I know
  1483. 54:08that he had access to a number of
  1484. 54:10documents that we sent documents to him.
  1485. 54:12Uh do you remember who at Theranos sent
  1486. 54:14him those documents?
  1487. 54:16I don't um but I I
  1488. 54:19um would assume that I sent some of them
  1489. 54:22to him.
  1490. 54:24Do you know if he passed those materials
  1491. 54:26on to
  1492. 54:27potential C2 investors?
  1493. 54:30I don't know if he passed them on. I
  1494. 54:32think he may have shown materials that
  1495. 54:35he had to certain potential investors.
  1496. 54:38Did Did you understand at the time that
  1497. 54:40materials were being provided to him
  1498. 54:42that he was intending to show those
  1499. 54:44materials to potential investors?
  1500. 54:47No, I think he did that later.
  1501. 54:50Did
  1502. 54:51Did he ever attend um meetings that you
  1503. 54:53had with
  1504. 54:55potential C2 investors at Theranos?
  1505. 54:57Yes.
  1506. 54:58Uh with anyone?
  1507. 54:59Yes.
  1508. 54:59Uh
  1509. 55:00would that include um
  1510. 55:02J- just for clarity's sake since there's
  1511. 55:04a
  1512. 55:05Uh sure, Cox Investments.
  1513. 55:07Yes.
  1514. 55:07Um who who else did he attend with?
  1515. 55:11Um he was at one of the meetings with uh
  1516. 55:16um it wasn't at Theranos, but it was um
  1517. 55:19about investing in Theranos um and
  1518. 55:23uh he may have been at at others as
  1519. 55:25well.
  1520. 55:26Uh did he attend a meeting with um
  1521. 55:29representatives from the Niarchos
  1522. 55:30Foundation?
  1523. 55:32Yes.
  1524. 55:33Uh
  1525. 55:34Yes, it it
  1526. 55:37In a
  1527. 55:37Actually, I think so. You may have been
  1528. 55:38on the phone. I'm not sure.
  1529. 55:41Um
  1530. 55:43did
  1531. 55:45in any of those meetings
  1532. 55:48do you recall presenting a selection of
  1533. 55:50the slides that we saw in exhibit 256?
  1534. 55:54I don't remember that, no.
  1535. 56:02Earlier in your testimony
  1536. 56:05you testified that BDT Capital was hired
  1537. 56:08as a financial advisor to Theranos. Do
  1538. 56:09you remember that testimony?
  1539. 56:11As an as an advisor initially, yes. Or
  1540. 56:14that we engaged with them. I don't know
  1541. 56:15if we hired them per se.
  1542. 56:18Okay. And in late 2014, you understood
  1543. 56:21that they were considering to invest in
  1544. 56:22Theranos, that they were a potential
  1545. 56:24investor as well, correct?
  1546. 56:26I did.
  1547. 56:28I'm going to hand to you what's been
  1548. 56:29marked as Theranos exhibit 266.
  1549. 56:40Is it a 266?
  1550. 56:42It purports to be a December 6 I'm
  1551. 56:45sorry, December 19th, 2014 email from
  1552. 56:49Elizabeth Holmes to Sunny Balwani.
  1553. 56:52Subject line is forward project test
  1554. 56:54company overview memo version 025.pdf
  1555. 56:59with starting Bates number THPFM
  1556. 57:020003891168.
  1557. 57:07With an attachment with Bates number
  1558. 57:09starting
  1559. 57:11THPFM 0003891169.
  1560. 57:16Have you seen exhibit 266 before?
  1561. 57:21I don't know. I I don't remember it, but
  1562. 57:23I don't have reason to doubt the email
  1563. 57:25exchange.
  1564. 57:26What is exhibit 266?
  1565. 57:30Um it looks like an email exchange.
  1566. 57:33Yeah, I'm with an attachment from you.
  1567. 57:42Did you receive the email on December
  1568. 57:4518th, 2014
  1569. 57:47from
  1570. 57:49on or about
  1571. 57:51December 18th, 2014?
  1572. 57:55Again, I don't remember it, but I assume
  1573. 57:56I did.
  1574. 57:58And you also received um
  1575. 58:00a following email around the same date
  1576. 58:02from
  1577. 58:04It looks like I did, yes.
  1578. 58:07Do you understand to where the addresses
  1579. 58:09on these emails
  1580. 58:12Yes.
  1581. 58:14So, you'll see here uh at the bottom of
  1582. 58:161168 on exhibit 266, there's an email
  1583. 58:21from to you.
  1584. 58:22And he says, "Elizabeth, attached is the
  1585. 58:25preliminary draft of our company
  1586. 58:26overview that we would plan to send to
  1587. 58:28the pre-approved co-investor targets."
  1588. 58:30Do you see that?
  1589. 58:32I do.
  1590. 58:36Did you understand that information that
  1591. 58:38they were including on this memo that
  1592. 58:40he's attaching to this email was based
  1593. 58:42on conversations that you had with you
  1594. 58:43and Mr. Balwani?
  1595. 58:47Again, I I don't remember
  1596. 58:49uh receiving this email and I I don't
  1597. 58:50know that I ever read the attachment.
  1598. 58:54Had you had discussions with Capital
  1599. 58:56prior to December
  1600. 58:5918th, 2014?
  1601. 59:01Yes.
  1602. 59:02And in those discussions, had you
  1603. 59:04described Theranos'
  1604. 59:07vision and its operations?
  1605. 59:10Yes.
  1606. 59:15Did you understand by the time of this
  1607. 59:17email that Capital had prepared a memo
  1608. 59:20in order to send out to potential
  1609. 59:22co-investors?
  1610. 59:25I I don't know. My My memory generally
  1611. 59:27is that we
  1612. 59:29were deciding whether or not to have
  1613. 59:30best and and ultimately decided not to
  1614. 59:32proceed.
  1615. 59:34Did you have any discussions with
  1616. 59:35Capital about them going out to find
  1617. 59:39co-investors to invest together in
  1618. 59:41Theranos with
  1619. 59:43Um my memory is that they already had
  1620. 59:45entities that were interested in
  1621. 59:47investing, um
  1622. 59:48but I don't remember specific
  1623. 59:50conversations about that.
  1624. 59:52Okay, so in Elizabeth's email at the
  1625. 59:54bottom, he says, "Feel free to make any
  1626. 59:56changes, edits." Do you see that?
  1627. 59:58Yes.
  1628. 1:00:00Did you end up making any changes to the
  1629. 1:00:02memorandum that he attached and sent and
  1630. 1:00:05Did you ever send that back to the
  1631. 1:00:07Capital?
  1632. 1:00:09Again, I don't recognize the document,
  1633. 1:00:11so I don't know that we ever went
  1634. 1:00:12through it. I think we ended up deciding
  1635. 1:00:14not to proceed with the financial
  1636. 1:00:16investment from
  1637. 1:00:18Okay, and after Elizabeth's email, then
  1638. 1:00:21he sends another email and she attaches
  1639. 1:00:23instead of a PDB PDF version of the
  1640. 1:00:25memorandum, she sends a Word version of
  1641. 1:00:27the document. Do you see that?
  1642. 1:00:30I do.
  1643. 1:00:30So, she was intending to make it easier
  1644. 1:00:32for you and Mr. Balwani or at least for
  1645. 1:00:34you to make changes to the document,
  1646. 1:00:35correct?
  1647. 1:00:36Yes.
  1648. 1:00:37Okay, and then you send it You forward
  1649. 1:00:39the email to Mr. Balwani. Do you see
  1650. 1:00:41that at the top?
  1651. 1:00:42Yes.
  1652. 1:00:42What was your purpose in sending it to
  1653. 1:00:44Mr. Balwani?
  1654. 1:00:46I don't know. I can't remember receiving
  1655. 1:00:47this email.
  1656. 1:00:53You can keep that in front of you.
  1657. 1:00:56I'm going to hand to you what's been
  1658. 1:00:58marked Theranos Exhibit 267.
  1659. 1:01:05Exhibit 267
  1660. 1:01:08purports to be
  1661. 1:01:10a December 23rd, 2014 email from to
  1662. 1:01:13Elizabeth Holmes with copy to Subject
  1663. 1:01:15line is Re: Follow-up to our call
  1664. 1:01:18with starting days number BDT SEC
  1665. 1:01:22_
  1666. 1:01:22PST 0005074.
  1667. 1:01:26Have you seen exhibit 267 before?
  1668. 1:01:30Um, I don't recognize it, but I don't
  1669. 1:01:32have reason to doubt the document.
  1670. 1:01:34And was he also a member of the DDT
  1671. 1:01:35team?
  1672. 1:01:36I think so.
  1673. 1:01:39So, if you look
  1674. 1:01:41um
  1675. 1:01:43on the bottom of exhibit 2675074,
  1676. 1:01:48there is an email from you on December
  1677. 1:01:5023rd, 2014.
  1678. 1:01:53Uh, did you send that email on or about
  1679. 1:01:55December 23rd, 2014?
  1680. 1:01:59Again, I don't remember it, but I don't
  1681. 1:02:00have reason to doubt the document.
  1682. 1:02:02Okay. And so, you're sending an email to
  1683. 1:02:05um
  1684. 1:02:07uh, it looks like
  1685. 1:02:09And here you you note in your email, see
  1686. 1:02:131 2 3, the fourth paragraph down, you
  1687. 1:02:15say, "With respect to the investment
  1688. 1:02:17memo, our team had a mini heart attack
  1689. 1:02:19seeing our complete strategy, future
  1690. 1:02:21plans, unannounced deals, and profit
  1691. 1:02:23margins delineated in a single document
  1692. 1:02:25like that, especially without any
  1693. 1:02:27encryption of the document. Do you see
  1694. 1:02:29that?
  1695. 1:02:30Yes.
  1696. 1:02:31Does this refresh your recollection that
  1697. 1:02:33you reviewed the memo
  1698. 1:02:34at the time?
  1699. 1:02:35No.
  1700. 1:02:37How would you know that the memo
  1701. 1:02:39included all of these things like
  1702. 1:02:41Theranos' complete strategy, future
  1703. 1:02:42plans, unannounced deals, and profit
  1704. 1:02:44margin uh, margins unless you reviewed
  1705. 1:02:46it?
  1706. 1:02:47Looks like our team reviewed it. I don't
  1707. 1:02:49know who.
  1708. 1:02:52Who on your team would have reviewed the
  1709. 1:02:54memo?
  1710. 1:02:55I don't know.
  1711. 1:02:56Who else received the memo besides you
  1712. 1:02:58and Mr. Balwani?
  1713. 1:02:59I don't know.
  1714. 1:03:01If you look a little further down in the
  1715. 1:03:02the that same paragraph, it
  1716. 1:03:04says, "Let me know if the if the intent
  1717. 1:03:07is for this to go only to persons who
  1718. 1:03:09have committed to participate
  1719. 1:03:12to a co-investment to a broader group.
  1720. 1:03:15Semicolon, I'd like to get a sense of
  1721. 1:03:16what the purpose of the document is at
  1722. 1:03:18this stage, and we can then send back
  1723. 1:03:20our thoughts and edits based on what
  1724. 1:03:22we're you're trying to do uh with it at
  1725. 1:03:24this point.
  1726. 1:03:26Do you see that?
  1727. 1:03:26Yes.
  1728. 1:03:27What what were you asking there?
  1729. 1:03:30So, now that you're reading it now, I
  1730. 1:03:32assume I'm saying what what is the
  1731. 1:03:33purpose of the document, and then we'll
  1732. 1:03:35edit it based on the intended audience.
  1733. 1:03:38Did you Did you not understand the
  1734. 1:03:39purpose of the document be-
  1735. 1:03:41before asking him?
  1736. 1:03:43I mean, I assume I did not, given that
  1737. 1:03:46I'm asking here.
  1738. 1:03:50So, going back to exhibit 266,
  1739. 1:03:55I want to turn to the attachment to the
  1740. 1:03:57email.
  1741. 1:03:58Yes.
  1742. 1:03:59And look at the page number ending with
  1743. 1:04:02page number ending 1172.
  1744. 1:04:12Oh, actually first, could you um
  1745. 1:04:14actually start on
  1746. 1:04:161169.
  1747. 1:04:24You'll see this is the cover page of the
  1748. 1:04:26memorandum.
  1749. 1:04:31And it's titled project test. Do you see
  1750. 1:04:33that?
  1751. 1:04:34Yes.
  1752. 1:04:35Did you understand in your discussions
  1753. 1:04:36with BDT Capital that they were using
  1754. 1:04:38test uh as a code name for Theranos?
  1755. 1:04:42I don't remember that, um but it looks
  1756. 1:04:45like it was.
  1757. 1:04:46Okay. Why don't you turn to 1172?
  1758. 1:04:55So, I want to focus on
  1759. 1:04:57uh the portion of this page under
  1760. 1:04:59compelling strategic plan.
  1761. 1:05:02You'll see on the third paragraph down,
  1762. 1:05:04it says,
  1763. 1:05:06"In conjunction with its execution of
  1764. 1:05:07its seven-pronged strategic plan, the
  1765. 1:05:10company is currently negotiating the
  1766. 1:05:11terms of the contract with the US
  1767. 1:05:13government to provide testing services
  1768. 1:05:15for Ebola within US airports and
  1769. 1:05:18alongside the US military and aid
  1770. 1:05:20agencies in West Africa.
  1771. 1:05:23Did you tell you this?
  1772. 1:05:27I don't remember a specific
  1773. 1:05:30um conversation to that effect.
  1774. 1:05:31Do you remember a general conversation
  1775. 1:05:33to that effect?
  1776. 1:05:35I I don't remember general conversations
  1777. 1:05:37to that effect. I know at the time we
  1778. 1:05:39were devoting a lot of resources to the
  1779. 1:05:41submission of an emergency use
  1780. 1:05:43authorization for Ebola and were hopeful
  1781. 1:05:46that we would be able to engage in
  1782. 1:05:47contracting opportunities.
  1783. 1:05:51So, you remember
  1784. 1:05:53that you were and you were hopeful about
  1785. 1:05:56engaging in contract opportunities. Were
  1786. 1:05:58you
  1787. 1:06:00Were you negotiating the terms of a
  1788. 1:06:01contract with the US government at that
  1789. 1:06:03time with respect to Ebola?
  1790. 1:06:07Not that I can recall.
  1791. 1:06:08So, would the statement be true as of
  1792. 1:06:11late 2014?
  1793. 1:06:15I don't think so, but I I can't remember
  1794. 1:06:17exactly who we were engaging with on
  1795. 1:06:20Ebola contracting.
  1796. 1:06:22Did
  1797. 1:06:23Who would know the answer to that?
  1798. 1:06:25Um
  1799. 1:06:27I don't know.
  1800. 1:06:28I don't know. We We need to look back at
  1801. 1:06:30um how we were doing this at that time.
  1802. 1:06:33I haven't thought about it for a long
  1803. 1:06:34time.
  1804. 1:06:36Did you hear Mr. Balwani make a
  1805. 1:06:38statement to this effect that the the
  1806. 1:06:39company is currently negotiating the
  1807. 1:06:41terms of a contract with the US
  1808. 1:06:42government with respect to Ebola?
  1809. 1:06:46I I can't remember any discussions to
  1810. 1:06:47that effect.
  1811. 1:06:50If you turn to the next page, which is
  1812. 1:06:521173
  1813. 1:06:56under technology and hardware, the
  1814. 1:06:58second paragraph down
  1815. 1:07:00the memorandum says, "Samples for all
  1816. 1:07:02tests are run on one proprietary
  1817. 1:07:04diagnostic machine, an unprecedented
  1818. 1:07:07capability in testing, and a significant
  1819. 1:07:09technological competitive advantage
  1820. 1:07:11versus peers. Did you tell me that?
  1821. 1:07:17Um to the extent we were discussing the
  1822. 1:07:18mini lab, um yes.
  1823. 1:07:21That's what the mini lab is architected
  1824. 1:07:22to do.
  1825. 1:07:24It says all tests are run on one
  1826. 1:07:27Is this an aspirational statement then
  1827. 1:07:29in your mind or
  1828. 1:07:31Um yes, it's a description of the design
  1829. 1:07:34of the mini lab. We
  1830. 1:07:36Yes.
  1831. 1:07:41Did you tell the capital that Theranos
  1832. 1:07:44was not actually using
  1833. 1:07:46its proprietary diagnostic machine to
  1834. 1:07:48perform patient tests?
  1835. 1:07:51Or all patient tests rather, that it was
  1836. 1:07:53only performed that it was it was only
  1837. 1:07:55being used perform a small subset of the
  1838. 1:07:57tests?
  1839. 1:07:58I don't think we had discussions about
  1840. 1:08:00what it was being used to do in the in
  1841. 1:08:02the clinical lab.
  1842. 1:08:04Why not?
  1843. 1:08:06Because the bulk of our focus was on
  1844. 1:08:08phase two of our model, and getting the
  1845. 1:08:10machine out and distributed.
  1846. 1:08:12The capital wasn't interested in what
  1847. 1:08:13Theranos was doing at the time?
  1848. 1:08:16I I don't know what they were interested
  1849. 1:08:18in. Did they ever ask you questions
  1850. 1:08:19about what Theranos was doing at the
  1851. 1:08:21time?
  1852. 1:08:22I again I can't remember the specifics
  1853. 1:08:24of the conversations with them.
  1854. 1:08:28Did you hear Mr. Balwani make a
  1855. 1:08:29statement like this to you that samples
  1856. 1:08:31of all tests are run on one proprietary
  1857. 1:08:33diagnostic machine?
  1858. 1:08:36Again, I can't remember the specifics of
  1859. 1:08:38conversations with
  1860. 1:08:41Return to 1174.
  1861. 1:08:51Under test accuracy, second paragraph
  1862. 1:08:53down, it says a validation study
  1863. 1:08:56published by Johns Hopkins in 2010
  1864. 1:08:59concluded that the the technology is
  1865. 1:09:01novel and sound. It can accurately run a
  1866. 1:09:03wide range of routine and special assays
  1867. 1:09:06and that no major weaknesses were
  1868. 1:09:08identified. Did you tell that there was
  1869. 1:09:10a validation study that was published by
  1870. 1:09:12Johns Hopkins in 2010 that concluded
  1871. 1:09:14that?
  1872. 1:09:17I don't think we told them. My memory is
  1873. 1:09:19they actually got access to the the
  1874. 1:09:22Johns Hopkins document in and of itself.
  1875. 1:09:25Your memory is that they got access to
  1876. 1:09:27the Johns Hopkins document. Are you
  1877. 1:09:28talking about the April 2010 document
  1878. 1:09:31document?
  1879. 1:09:32I I think so. Yeah.
  1880. 1:09:33How did they gain access to that
  1881. 1:09:35document?
  1882. 1:09:36I'm not sure if we gave it to them or
  1883. 1:09:38somebody else gave it to them. I'm not
  1884. 1:09:39sure.
  1885. 1:09:41Did you ever describe the
  1886. 1:09:45the April 2010 document from Johns
  1887. 1:09:47Hopkins as a validation study?
  1888. 1:09:51I don't remember specific conversations
  1889. 1:09:53to that effect.
  1890. 1:09:55Other than the Johns Hopkins report, do
  1891. 1:09:57you do you remember anything else that
  1892. 1:09:58was provided to
  1893. 1:10:01I don't. I I know we were actively
  1894. 1:10:03engaged with them over a period of
  1895. 1:10:05months on a lot of different aspects of
  1896. 1:10:06our business, so I'm sure they had
  1897. 1:10:08access to a lot of content.
  1898. 1:10:11Did you hear Mr. Balwani make the
  1899. 1:10:13statement to you that there was a
  1900. 1:10:15validation study that was published by
  1901. 1:10:16Johns Hopkins in 2010?
  1902. 1:10:19Not that I can remember.
  1903. 1:10:22On that same page under select clinical
  1904. 1:10:24correlations,
  1905. 1:10:26the memorandum states
  1906. 1:10:28The company has validated all of its
  1907. 1:10:29tests versus traditional laboratory and
  1908. 1:10:32reference methods to demonstrate their
  1909. 1:10:34accuracy.
  1910. 1:10:36Did you tell this?
  1911. 1:10:38I don't know.
  1912. 1:10:41Was this true in
  1913. 1:10:43December 2014?
  1914. 1:10:47I might Again, I haven't read the
  1915. 1:10:49document, so I'm not sure specifically
  1916. 1:10:51whether this is referring to product
  1917. 1:10:52development or
  1918. 1:10:54the clinical lab. I'm we we thought had
  1919. 1:10:57done this
  1920. 1:10:58I'm both in tests we developed on the
  1921. 1:11:01product development side as well as
  1922. 1:11:03tests we had validated as LDTs in the
  1923. 1:11:06clinical lab.
  1924. 1:11:07Did you make clear to B at this time in
  1925. 1:11:09December or late 2014 that the clinical
  1926. 1:11:13the clinical data that you were showing
  1927. 1:11:15them pertained to
  1928. 1:11:17uh
  1929. 1:11:18data that was generated in the R&D lab
  1930. 1:11:21and not in the clinical lab that was
  1931. 1:11:24performing to patient testing?
  1932. 1:11:26I I don't know if we showed them data
  1933. 1:11:28from the lab the LDTs or R&D data.
  1934. 1:11:31Certainly to the extent that we showed
  1935. 1:11:34R&D data, my memory is we generally
  1936. 1:11:35would describe it as product development
  1937. 1:11:38data and all the tests we created.
  1938. 1:11:45Turning to
  1939. 1:11:47page 1175
  1940. 1:11:50under manufacturing
  1941. 1:11:53the memorandum states "Theranos
  1942. 1:11:55currently manufactures 100% of its
  1943. 1:11:57diagnostic machines and associated
  1944. 1:11:59consumables in a single plant in Newark,
  1945. 1:12:02California." Do you Did you tell B
  1946. 1:12:04Capital that Theranos currently
  1947. 1:12:06manufactured 100% of its diagnostic
  1948. 1:12:09machines in Newark, California
  1949. 1:12:12as of December 2014?
  1950. 1:12:15To the extent it's referring to
  1951. 1:12:17the mini lab and all of the components
  1952. 1:12:19in the mini lab.
  1953. 1:12:22What
  1954. 1:12:23You did You did tell B Capital that?
  1955. 1:12:25I I don't know that I personally said
  1956. 1:12:27that, but
  1957. 1:12:28that was something that Theranos was
  1958. 1:12:29very proud of that every component of
  1959. 1:12:31mini lab was manufactured in
  1960. 1:12:34this Newark facility.
  1961. 1:12:36The mini lab wasn't 100% of Theranos'
  1962. 1:12:39diagnostic machines at the time, was it?
  1963. 1:12:43No. Um just 100% of the mini lab was
  1964. 1:12:47manufactured in the Newark facility.
  1965. 1:12:50So was the statement true as of December
  1966. 1:12:522014?
  1967. 1:12:55Um only with respect to the mini lab.
  1968. 1:13:00The statement isn't qualified with
  1969. 1:13:02respect to mini lab, is it?
  1970. 1:13:05No, again, I I I don't think I've ever
  1971. 1:13:08read this whole document, so I'm not
  1972. 1:13:09sure
  1973. 1:13:11if this is talking about the clinical
  1974. 1:13:13lab or the technology we were working to
  1975. 1:13:14develop.
  1976. 1:13:19Did you ever hear Mr. Balwani make this
  1977. 1:13:21statement to Capital?
  1978. 1:13:23Not that I can remember.
  1979. 1:13:26Uh
  1980. 1:13:27the third paragraph down, it says,
  1981. 1:13:29"Unlike other sector participants, Test
  1982. 1:13:32operates a vertically integrated
  1983. 1:13:34manufacturing model.
  1984. 1:13:36The company receives raw materials,
  1985. 1:13:39e.g., plastic, aluminum, etc., and
  1986. 1:13:41constructs each and every component of
  1987. 1:13:43the finished products,
  1988. 1:13:44diagnostic machines, and associated
  1989. 1:13:46consumables." Did you tell V this?
  1990. 1:13:49Again, I I don't remember specific
  1991. 1:13:51conversations with
  1992. 1:13:53Did you hear Mr. Balwani make this
  1993. 1:13:55statement to
  1994. 1:13:55Not that I can remember.
  1995. 1:13:57Was the statement true as of December
  1996. 1:13:582014?
  1997. 1:14:00With respect to our mini lab.
  1998. 1:14:03Is the statement in any way qualified
  1999. 1:14:05with respect to the mini lab?
  2000. 1:14:08Again, I I haven't read this document,
  2001. 1:14:10so I don't know what the pretext to this
  2002. 1:14:12is.
  2003. 1:14:13This section um just talks about uh
  2004. 1:14:18diagnostic machines.
  2005. 1:14:21And Theranos was using other diagnostic
  2006. 1:14:23machines besides the mini lab in
  2007. 1:14:25December 2014, correct?
  2008. 1:14:27In its clinical lab, yes.
  2009. 1:14:34If you turn to 1178
  2010. 1:14:37and 1179,
  2011. 1:14:40starting on page 1178, there's a section
  2012. 1:14:44called Walgreens. Do you see that
  2013. 1:14:46halfway down the page?
  2014. 1:14:47Yes.
  2015. 1:14:48Okay, if you flip over to 1179 very top.
  2016. 1:14:55The very top of the page there's a
  2017. 1:14:57sentence that starts the contract does
  2018. 1:14:59not limit.
  2019. 1:15:02So, the memo is talking about Walgreens
  2020. 1:15:04and it says that the contract does not
  2021. 1:15:06limit or restrict tests from opening
  2022. 1:15:08additional locations if the company
  2023. 1:15:10chooses to do so.
  2024. 1:15:12Did you tell Capital that?
  2025. 1:15:14In December? Uh around December 2014.
  2026. 1:15:18I don't think so. My memory is we gave
  2027. 1:15:19them access to the Walgreens agreement
  2028. 1:15:21and they reviewed it directly.
  2029. 1:15:23Did you hear Mr. Balwani make this
  2030. 1:15:25statement to the Capital?
  2031. 1:15:26No, again I I don't remember any
  2032. 1:15:27specifics of the conversations.
  2033. 1:15:29Okay.
  2034. 1:15:30Was the statement true as of December
  2035. 1:15:322014?
  2036. 1:15:36Do you mind if I read the paragraph?
  2037. 1:15:38Sure.
  2038. 1:16:08I don't know.
  2039. 1:16:11Was it true that
  2040. 1:16:15the contract
  2041. 1:16:16the Walgreens contract didn't doesn't
  2042. 1:16:20restrict Theranos from opening
  2043. 1:16:21additional locations if Theranos chose
  2044. 1:16:23to do so?
  2045. 1:16:27I don't know.
  2046. 1:16:29Wasn't it true that Walgreens and
  2047. 1:16:30Theranos had to work together to plan
  2048. 1:16:32out additional locations together?
  2049. 1:16:36I I I yes, I remember that in certain
  2050. 1:16:38versions of the contract. I'm not
  2051. 1:16:41sure what this is referring to.
  2052. 1:16:45So, if you look down another
  2053. 1:16:49two paragraphs from there,
  2054. 1:16:51the memorandum states, "As part of the
  2055. 1:16:53agreement" and this is talking about the
  2056. 1:16:55Walgreens agreement again, "the two
  2057. 1:16:57companies will partner together to make
  2058. 1:16:59Test the largest clinical laboratory in
  2059. 1:17:02the US. This development is on target
  2060. 1:17:04and the two companies anticipate
  2061. 1:17:06achieving this milestone by the end of
  2062. 1:17:082016."
  2063. 1:17:09Did you tell Capital all that in late
  2064. 1:17:112014?
  2065. 1:17:14Um I don't think so.
  2066. 1:17:17Did you hear Mr. Balwani make this
  2067. 1:17:18statement to Capital?
  2068. 1:17:19I I can't remember the specifics of
  2069. 1:17:21conversations.
  2070. 1:17:23Was the statement true as of December
  2071. 1:17:252014?
  2072. 1:17:26I don't know.
  2073. 1:17:30Do you ever recall a time in which uh
  2074. 1:17:31Walgreens
  2075. 1:17:33stated it was going to make Theranos the
  2076. 1:17:35largest clinical laboratory in the US?
  2077. 1:17:40Um
  2078. 1:17:41certainly
  2079. 1:17:43the the prior
  2080. 1:17:46um
  2081. 1:17:48Walgreens management team had that
  2082. 1:17:50vision. I don't remember specific
  2083. 1:17:51conversations uh to that effect.
  2084. 1:17:55So, the vision would be the sort of the
  2085. 1:17:57pre-Boots leadership?
  2086. 1:17:58Yes.
  2087. 1:18:01So, if you look down another paragraph
  2088. 1:18:04under that uh in the middle of the next
  2089. 1:18:06paragraph it says,
  2090. 1:18:08"In 2015, the company plans to
  2091. 1:18:10dramatically expand its wellness center
  2092. 1:18:13penetration to several hundred stores
  2093. 1:18:15across multiple states."
  2094. 1:18:18Did you tell Capital
  2095. 1:18:19that
  2096. 1:18:23No, I don't think so.
  2097. 1:18:24Did you hear Mr. Balwani make that
  2098. 1:18:26statement to Capital?
  2099. 1:18:28Um I I can't remember any of the
  2100. 1:18:29specifics of the conversations.
  2101. 1:18:31Was that statement true as of December
  2102. 1:18:332014?
  2103. 1:18:36Um I again, my read on this, sitting
  2104. 1:18:39here now, is that this was the
  2105. 1:18:41conclusions they drew from reading the
  2106. 1:18:42contract themselves.
  2107. 1:18:45But you don't have any recollection that
  2108. 1:18:47that's the basis for the statement here.
  2109. 1:18:49I I don't. I just remember giving them
  2110. 1:18:51access to the agreement.
  2111. 1:18:53Okay, so we know we talked about the the
  2112. 1:18:54agreement and then the Johns Hopkins
  2113. 1:18:56report. Do you remember giving them
  2114. 1:18:57access to any other information?
  2115. 1:19:01Um
  2116. 1:19:03I'm just thinking.
  2117. 1:19:05Um
  2118. 1:19:11I I don't know specifically. I I
  2119. 1:19:13generally remember that because we had
  2120. 1:19:15met them in the context of wanting them
  2121. 1:19:17to advise us that we gave them broad
  2122. 1:19:19access to a lot of content internally. I
  2123. 1:19:22I don't I can't sit here and remember
  2124. 1:19:23another specific document.
  2125. 1:19:27So if you turn the page to 1180.
  2126. 1:19:31About a third down the page, there's a
  2127. 1:19:33section on Safeway. Do you see that?
  2128. 1:19:35Mhm.
  2129. 1:19:36The second paragraph starts, "The
  2130. 1:19:37company projects to launch wellness
  2131. 1:19:39centers within Safeway stores in 2015
  2132. 1:19:42beginning in California." Did you tell
  2133. 1:19:44Le Capital that?
  2134. 1:19:48I don't think so.
  2135. 1:19:50Did Mr. Balwani
  2136. 1:19:51tell Le Capital that?
  2137. 1:19:53I don't know.
  2138. 1:19:55Was that statement true as of December
  2139. 1:19:562014?
  2140. 1:19:58I don't know.
  2141. 1:20:02Going on to
  2142. 1:20:04page with Bates numbering 1183.
  2143. 1:20:10You'll see there is a table here in the
  2144. 1:20:12middle of the page that's titled company
  2145. 1:20:14projections. Do you see that?
  2146. 1:20:16Yes.
  2147. 1:20:19And this shows that Theranos is earning
  2148. 1:20:25uh $8 million from physicians' offices
  2149. 1:20:29and uh $43 million from hospital courier
  2150. 1:20:33services in
  2151. 1:20:35the fourth quarter of 2014. Do you see
  2152. 1:20:37that?
  2153. 1:20:38I do.
  2154. 1:20:39Did you provide these projections to be
  2155. 1:20:42No.
  2156. 1:20:44Did Mr. Balwani provide these
  2157. 1:20:45projections to you?
  2158. 1:20:46I don't know.
  2159. 1:20:48Were these projections reasonable in
  2160. 1:20:50December 2014 that Theranos was set to
  2161. 1:20:54make $8 million in revenue from
  2162. 1:20:56physicians' offices and $43 million
  2163. 1:20:58from hospitals uh,
  2164. 1:21:01through couriering uh, samples?
  2165. 1:21:03I don't think so.
  2166. 1:21:05Why not?
  2167. 1:21:06I I don't think we um,
  2168. 1:21:09deployed the retail locations to do this
  2169. 1:21:11in
  2170. 1:21:122014.
  2171. 1:21:16Did Theranos end up earning any revenues
  2172. 1:21:19from these two sectors in fourth quarter
  2173. 1:21:212014?
  2174. 1:21:23I don't know.
  2175. 1:21:27You'll also see that
  2176. 1:21:31on the same page on the company
  2177. 1:21:33projections
  2178. 1:21:35page
  2179. 1:21:37in that same table we were looking at
  2180. 1:21:38under pharmaceutical services
  2181. 1:21:41there's a projection of $8 million
  2182. 1:21:43for pharmaceutical services in uh,
  2183. 1:21:46fourth quarter of 2014 for a total of
  2184. 1:21:49$40 million projected revenues in
  2185. 1:21:52uh, 2014 for the year. See that?
  2186. 1:21:55Mhm.
  2187. 1:21:56Did you tell Capital that Theranos was
  2188. 1:21:58on the road to achieving $40 million
  2189. 1:22:02uh, in revenues from the pharmaceutical
  2190. 1:22:04services?
  2191. 1:22:05I don't think so.
  2192. 1:22:06Did you hear Mr. Balwani
  2193. 1:22:09make that statement to
  2194. 1:22:10Uh, again, I I can't remember any of the
  2195. 1:22:12specifics of the conversations I had.
  2196. 1:22:15So, if you look at those two numbers, it
  2197. 1:22:18would appear that Theranos would have
  2198. 1:22:20generated about $32 million
  2199. 1:22:23in revenues from pharmaceutical services
  2200. 1:22:25for the rest of the year, uh, first
  2201. 1:22:27quarter to third quarter of 2014. Do you
  2202. 1:22:29see that?
  2203. 1:22:31I do.
  2204. 1:22:33Had Theranos
  2205. 1:22:35um and generated $32 million from
  2206. 1:22:38pharmaceutical services
  2207. 1:22:40in first quarter to third quarter 2014?
  2208. 1:22:44I don't think so.
  2209. 1:22:48So, if you look on the bottom of the
  2210. 1:22:49page
  2211. 1:22:51under retail pharmacies
  2212. 1:22:53the memorandum states Walgreens
  2213. 1:22:55locations
  2214. 1:22:57test currently has 41 wellness centers
  2215. 1:22:59in Walgreens stores, 40 in Arizona, one
  2216. 1:23:02in Palo Alto, California, and plans to
  2217. 1:23:05open wellness centers in 900 total
  2218. 1:23:07Walgreens pharmacies by year end 2015.
  2219. 1:23:10Did you tell Capital this?
  2220. 1:23:13I don't think so.
  2221. 1:23:15Did you hear Mr. Balwani make this
  2222. 1:23:16statement to Capital?
  2223. 1:23:18Again, I can't remember any specifics of
  2224. 1:23:20the conversations with
  2225. 1:23:22Was this a true statement that Theranos
  2226. 1:23:24was planning to open wellness centers in
  2227. 1:23:25900 total Walgreens pharmacies by year
  2228. 1:23:28end 2015?
  2229. 1:23:32I don't know.
  2230. 1:23:38If you turn the page to 1184
  2231. 1:23:42under physicians offices
  2232. 1:23:46second bullet point down, it says
  2233. 1:23:48locations. The company is currently in
  2234. 1:23:50101 physician offices and plans to be in
  2235. 1:23:53approximately 700 offices by year end
  2236. 1:23:552015.
  2237. 1:23:57Did you tell Capital this?
  2238. 1:23:59No.
  2239. 1:24:00Did you hear Mr. Balwani make this
  2240. 1:24:01statement to Capital?
  2241. 1:24:02I don't think so.
  2242. 1:24:03Was the statement true as of December
  2243. 1:24:062014?
  2244. 1:24:10I don't know. I think
  2245. 1:24:12if we were doing physician pickup, it
  2246. 1:24:14would have been reflective of that. I
  2247. 1:24:15don't know when we were doing that.
  2248. 1:24:17Was Theranos currently at that time in
  2249. 1:24:20December 2014 in 101 physician's
  2250. 1:24:23offices.
  2251. 1:24:24I don't know.
  2252. 1:24:27Was it ever?
  2253. 1:24:29We were picking up samples from
  2254. 1:24:31physician offices. I don't know how many
  2255. 1:24:32physician offices we were picking up
  2256. 1:24:34from.
  2257. 1:24:37If you
  2258. 1:24:38Uh turn to the next page, 1185.
  2259. 1:24:41Under pharmaceutical services, the first
  2260. 1:24:43bullet point says cartridges,
  2261. 1:24:45Theranos currently runs 3,000 samples
  2262. 1:24:48per month, 100 per day. Given current
  2263. 1:24:51contracts, it expects that's this number
  2264. 1:24:53to increase to 5,000 in the second half
  2265. 1:24:55of 2015.
  2266. 1:24:57Did you tell Capital
  2267. 1:24:59that Theranos was currently running
  2268. 1:25:013,000 samples from per month uh
  2269. 1:25:05under pharmaceutical services contracts?
  2270. 1:25:08No.
  2271. 1:25:09Did you hear Mr. Balwani make this
  2272. 1:25:11statement to Capital?
  2273. 1:25:12Not that I can remember.
  2274. 1:25:13Was the statement true as of December
  2275. 1:25:152015?
  2276. 1:25:16I'm sorry.
  2277. 1:25:17Was this Was this accurate in December
  2278. 1:25:192014?
  2279. 1:25:22Um
  2280. 1:25:25No, I don't I don't think so.
  2281. 1:25:37Did you ever tell the Capital that given
  2282. 1:25:39current contracts in pharmaceutical
  2283. 1:25:41services that Theranos expected the
  2284. 1:25:44number of samples run each month to
  2285. 1:25:46increase to 5,000 in the second half of
  2286. 1:25:492015?
  2287. 1:25:50I don't think so.
  2288. 1:25:52Did you ever hear uh Mr. Balwani make
  2289. 1:25:54that statement to the Capital?
  2290. 1:25:56Not that I can remember.
  2291. 1:25:58Was the statement true as of December
  2292. 1:26:002014?
  2293. 1:26:01I don't know.
  2294. 1:26:09You mentioned earlier that there were
  2295. 1:26:12others on your team who might have
  2296. 1:26:13reviewed the the memorandum and told you
  2297. 1:26:15that it included complete uh
  2298. 1:26:18notes about Theranos' complete strategy,
  2299. 1:26:21future plans, unannounced deals, and
  2300. 1:26:22profit margins. Do you remember that
  2301. 1:26:24testimony?
  2302. 1:26:26Uh just that I was inferring that from
  2303. 1:26:27the email you showed me.
  2304. 1:26:30So, you don't know whether somebody
  2305. 1:26:31might have told you that?
  2306. 1:26:33I again I don't remember sending this
  2307. 1:26:35email and just looking at the language
  2308. 1:26:37in it now and the fact that I said our
  2309. 1:26:39team as opposed to I uh
  2310. 1:26:43likely means that.
  2311. 1:26:45Did anyone raise any issues with respect
  2312. 1:26:47to the accuracy of the statements made
  2313. 1:26:49in this memorandum to you
  2314. 1:26:51from your team?
  2315. 1:26:53I I honestly don't know that we read the
  2316. 1:26:55memoranda
  2317. 1:26:57in detail. It looks like some people
  2318. 1:26:59looked at it, but I don't remember ever
  2319. 1:27:01reading it.
  2320. 1:27:04It We we we spoke before about you
  2321. 1:27:06having a lot of access to information at
  2322. 1:27:07Theranos, right?
  2323. 1:27:08Yeah.
  2324. 1:27:09And uh at this time they were they'd
  2325. 1:27:11been working with the company for some
  2326. 1:27:12time. Is that fair?
  2327. 1:27:14Yes.
  2328. 1:27:15Uh a few months.
  2329. 1:27:16The
  2330. 1:27:17in that in those few months you met with
  2331. 1:27:18Balwani times. Is that fair?
  2332. 1:27:20Yes.
  2333. 1:27:20And with his associates several times.
  2334. 1:27:23I I think so, yes.
  2335. 1:27:24And it was your understanding Mr.
  2336. 1:27:25Balwani did the same?
  2337. 1:27:27Yes.
  2338. 1:27:27Uh it it it does it concern you at all
  2339. 1:27:30that this is the impression they formed
  2340. 1:27:31on the company
  2341. 1:27:33given the level of interaction they had
  2342. 1:27:36by December 2014?
  2343. 1:27:38I
  2344. 1:27:39I'm a little bit confused by it. I'm I'm
  2345. 1:27:41not quite sure
  2346. 1:27:44where it's coming from or if it was just
  2347. 1:27:47intended to be a sales piece that we
  2348. 1:27:49were to edit. I'm I'm not I'm not sure.
  2349. 1:27:54Certainly I
  2350. 1:27:55I
  2351. 1:27:56don't think we conveyed some of the
  2352. 1:27:58things that were in it.
  2353. 1:28:01Did it concern you that they were
  2354. 1:28:03intending to send that memorandum to
  2355. 1:28:05co-investors even though it included
  2356. 1:28:07some inaccurate statements?
  2357. 1:28:10Again, I don't know that I read it at
  2358. 1:28:11the time. Um we certainly would have
  2359. 1:28:14wanted to make sure it was accurate if
  2360. 1:28:15it were going to have gone out.
  2361. 1:28:18Why didn't you review it and and make
  2362. 1:28:20changes and edits to it considering that
  2363. 1:28:22they asked you to do that?
  2364. 1:28:24I think at this time we were
  2365. 1:28:26um
  2366. 1:28:28beginning to think that we were not
  2367. 1:28:29going to be doing a deal with so we
  2368. 1:28:30weren't paying a lot of attention to it.
  2369. 1:28:32Did you tell them at that time that you
  2370. 1:28:34weren't going to be doing a deal with
  2371. 1:28:35them?
  2372. 1:28:36I think a couple weeks later or a week
  2373. 1:28:38or so later.
  2374. 1:28:40You you continued to meet with them in
  2375. 1:28:41late December 2014 time period, right?
  2376. 1:28:43I think so, yes.
  2377. 1:28:44Did they ask you again for your feedback
  2378. 1:28:46on this document?
  2379. 1:28:47I don't know.
  2380. 1:28:48Uh did anyone from
  2381. 1:28:50I don't know.
  2382. 1:28:54Did you ever tell PFM in early 2014 that
  2383. 1:28:58Theranos had 300 machines that were
  2384. 1:29:00running in Theranos' labs?
  2385. 1:29:05Uh not that I can remember.
  2386. 1:29:06Did you hear Sunny Balwani make this
  2387. 1:29:08statement to PFM?
  2388. 1:29:10Not that I can remember.
  2389. 1:29:15Did you ever tell PFM in early 2014 that
  2390. 1:29:18Theranos had the capability to
  2391. 1:29:19manufacture 200 mini labs?
  2392. 1:29:22Not that I can remember.
  2393. 1:29:23Did you hear Sunny Balwani make this
  2394. 1:29:25statement to PFM?
  2395. 1:29:28Uh again, I can't remember specifics of
  2396. 1:29:30the conversation with PFM.
  2397. 1:29:31Was that statement true as of January
  2398. 1:29:332014?
  2399. 1:29:35I don't know.
  2400. 1:29:42Did you ever tell PFM that Theranos had
  2401. 1:29:45a road map to 1,300 assays?
  2402. 1:29:49I don't know.
  2403. 1:29:50Did you hear Sunny Balwani make that
  2404. 1:29:51statement to PFM?
  2405. 1:29:54Not that I can remember.
  2406. 1:29:55Would this statement have been true as
  2407. 1:29:57of January 2014?
  2408. 1:30:01In a product development sense, yes.
  2409. 1:30:06Did you ever tell PFM in January 2014
  2410. 1:30:10that Theranos had developed almost all
  2411. 1:30:12of the 1,300 assays and had launched
  2412. 1:30:15some of the 1,300 assays?
  2413. 1:30:19I don't remember specific discussions to
  2414. 1:30:21that effect.
  2415. 1:30:22Did you hear Mr. Balwani ever make that
  2416. 1:30:24statement to PFM?
  2417. 1:30:26Not that I can remember.
  2418. 1:30:27Was that statement true as of January
  2419. 1:30:282014?
  2420. 1:30:29It's actually a compound compound
  2421. 1:30:31statement. There's multiple quite
  2422. 1:30:33multiple statements there.
  2423. 1:30:34Sure, we can go through them one by one.
  2424. 1:30:36So, did you ever tell PFM that Theranos
  2425. 1:30:38developed 1,300 assays?
  2426. 1:30:42No.
  2427. 1:30:43Did you ever hear Mr. Balwani make that
  2428. 1:30:44statement to PFM?
  2429. 1:30:46Not that I can remember.
  2430. 1:30:47Was that statement true as of January
  2431. 1:30:482014?
  2432. 1:30:50No.
  2433. 1:30:54Did you ever tell PFM that
  2434. 1:30:59Theranos can put
  2435. 1:31:04Let's write that.
  2436. 1:31:10The Duran partners was a seed two
  2437. 1:31:11investor, correct?
  2438. 1:31:12Yes.
  2439. 1:31:14And and Greg Penner was the member of
  2440. 1:31:16the Walton family that was considering
  2441. 1:31:18an investment in Theranos on behalf of
  2442. 1:31:20the Duran partners?
  2443. 1:31:22I think Greg and Rob both, yes.
  2444. 1:31:24Greg and Rob both, yeah. You were in
  2445. 1:31:26discussions with both Mr. Penner and Mr.
  2446. 1:31:28Walton in the fall of 2014 to invest in
  2447. 1:31:32Theranos?
  2448. 1:31:32Yes.
  2449. 1:31:34Did you ever tell Mr. Penner that
  2450. 1:31:37Theranos could execute just with the
  2451. 1:31:39cash that it had at the time and the
  2452. 1:31:42cash flow that it had achieved through
  2453. 1:31:43its contracts?
  2454. 1:31:46In the fall of 2014? Yes.
  2455. 1:31:49Um, I don't know.
  2456. 1:31:51Did you ever hear Mr. Balwani make that
  2457. 1:31:53statement?
  2458. 1:31:55I don't know.
  2459. 1:31:56Would that have been true in
  2460. 1:31:59late 2014?
  2461. 1:32:02Um, I don't know.
  2462. 1:32:28Did you ever tell Capital
  2463. 1:32:30in September of 2014
  2464. 1:32:33that Theranos' goal was to be in 800
  2465. 1:32:35stores by the end of 2015?
  2466. 1:32:38I don't know. Did you ever hear Mr.
  2467. 1:32:40Balwani make that statement?
  2468. 1:32:43Not that I can remember.
  2469. 1:32:45Did you ever tell Capital that Theranos'
  2470. 1:32:48machines cost 35 to 40,000 dollars
  2471. 1:32:52versus a million dollars for Theranos'
  2472. 1:32:55competitors?
  2473. 1:32:58Not that I can remember. Did you ever
  2474. 1:32:59hear Mr. Balwani make that statement to
  2475. 1:33:01Capital? I don't know.
  2476. 1:33:03Was that statement true that Theranos'
  2477. 1:33:05machines cost 35 to 40,000 dollars?
  2478. 1:33:10That's That's in the range of the what
  2479. 1:33:12the cost of goods of the mini lab likely
  2480. 1:33:14was at that time.
  2481. 1:33:16So, that Sorry. Go ahead.
  2482. 1:33:17What do you mean by cost of goods?
  2483. 1:33:19Um, the
  2484. 1:33:21the cost to make a a mini lab.
  2485. 1:33:24Uh, just the components or the labor and
  2486. 1:33:28I I believe all of the above that fully
  2487. 1:33:30loaded cost of goods.
  2488. 1:33:33Did you ever tell
  2489. 1:33:35Capital that
  2490. 1:33:37all of Theranos' devices work on one
  2491. 1:33:40box,
  2492. 1:33:41um,
  2493. 1:33:42which is a significant advantage versus
  2494. 1:33:44Theranos' competitors?
  2495. 1:33:46I'm not sure I understand the question.
  2496. 1:33:48All of the devices?
  2497. 1:33:50Maybe it's all of their tests. Did you
  2498. 1:33:51ever tell Capital that all of your tests
  2499. 1:33:53work on one box?
  2500. 1:33:55Which is different from your
  2501. 1:33:56competitors.
  2502. 1:33:57I don't remember saying that, but that's
  2503. 1:33:59what the mini lab is designed to do.
  2504. 1:34:03Did you ever hear Mr. Balwani make that
  2505. 1:34:05statement to Capital?
  2506. 1:34:06I don't know.
  2507. 1:34:12Did you ever tell Capital that Theranos
  2508. 1:34:14solves a fundamental problem for the
  2509. 1:34:16military?
  2510. 1:34:18Because Theranos can run tests quickly
  2511. 1:34:20on one portable machine where no one
  2512. 1:34:22else can.
  2513. 1:34:24I don't know.
  2514. 1:34:25If he said that.
  2515. 1:34:26Mr. Did you ever hear Mr. Balwani make
  2516. 1:34:28that statement?
  2517. 1:34:29I don't know.
  2518. 1:34:31Did you ever tell Capital that all of
  2519. 1:34:34Theranos' tests can be run on one
  2520. 1:34:35machine with one disposable cartridge?
  2521. 1:34:39Again, I I don't remember the specifics
  2522. 1:34:41of conversations, but that's what mini
  2523. 1:34:43lab is designed to do.
  2524. 1:34:45Did you ever hear Mr. Balwani make that
  2525. 1:34:47statement?
  2526. 1:34:48I don't know.
  2527. 1:34:50So, of course that wouldn't have applied
  2528. 1:34:51to the tests that Theranos was
  2529. 1:34:53conducting in patient testing, correct?
  2530. 1:34:57Repeat that question again. Sorry.
  2531. 1:34:59What do you mean?
  2532. 1:35:00So, it's not true that all of all of
  2533. 1:35:02Theranos' tests were being performed on
  2534. 1:35:04the mini lab, correct?
  2535. 1:35:06Correct.
  2536. 1:35:07That a majority of the tests were
  2537. 1:35:08actually performed on commercially
  2538. 1:35:09available machines, correct?
  2539. 1:35:11Absolutely.
  2540. 1:35:26What is Fremont Group?
  2541. 1:35:29It's a fund that manages mostly the
  2542. 1:35:32Bechtel family money.
  2543. 1:35:34Were you in discussions in late 2014
  2544. 1:35:37about a possible investment in Theranos
  2545. 1:35:39from Fremont Group?
  2546. 1:35:41Yes.
  2547. 1:35:42Who were your discussions with?
  2548. 1:35:44Um primarily
  2549. 1:35:45Was there anyone else who was involved
  2550. 1:35:47in those discussions?
  2551. 1:35:48Um there was
  2552. 1:35:51and I I don't remember the names of the
  2553. 1:35:52principals.
  2554. 1:35:53Was one of them?
  2555. 1:35:54I think so.
  2556. 1:35:58Do you remember the other?
  2557. 1:36:00I don't know.
  2558. 1:36:02Did you give Fremont Group a copy of
  2559. 1:36:04Theranos' financial model which showed
  2560. 1:36:06projections?
  2561. 1:36:08I did not. I I don't know if
  2562. 1:36:12I did not. I don't know if anyone else
  2563. 1:36:14at Theranos did.
  2564. 1:36:15Did Sunny Balwani provide financial
  2565. 1:36:18projections to Fremont Group?
  2566. 1:36:20I don't know.
  2567. 1:36:23Did you tell Fremont Group in late 2014
  2568. 1:36:26that the financial numbers
  2569. 1:36:29that Theranos' financial numbers were
  2570. 1:36:31based on no new contracts?
  2571. 1:36:35I don't think No.
  2572. 1:36:37Did you hear Mr. Balwani make the
  2573. 1:36:38statement to Fremont Group in late 2014?
  2574. 1:36:41Not that I can remember.
  2575. 1:36:42Was this statement true as of late 2014?
  2576. 1:36:47I don't know.
  2577. 1:36:49Did you tell anyone from the Fremont
  2578. 1:36:50Group that Theranos' assay run test time
  2579. 1:36:53was always less than 1 hour?
  2580. 1:36:56I don't know.
  2581. 1:36:57Would that Do you recall Mr. Balwani
  2582. 1:36:58saying that to anyone from the Fremont
  2583. 1:37:00Group?
  2584. 1:37:01Not that I can recall.
  2585. 1:37:02Would Would that have been a true
  2586. 1:37:03statement in October of 2014?
  2587. 1:37:07Um, to the extent we were talking about
  2588. 1:37:09the design of the mini lab, but not
  2589. 1:37:12testing our clinical lab.
  2590. 1:37:16Did you tell Fremont Group
  2591. 1:37:19Let me start again. Did you tell Fremont
  2592. 1:37:21Group in late 2014 that devices now cost
  2593. 1:37:25$40,000 fully loaded?
  2594. 1:37:29Not that I can remember.
  2595. 1:37:30Did you hear Mr. Balwani make that
  2596. 1:37:32statement to Fremont Group?
  2597. 1:37:34I don't know.
  2598. 1:37:35Was that statement true in late 2014?
  2599. 1:37:39I don't know.
  2600. 1:37:45Did you tell Fremont Group in late 2014
  2601. 1:37:48that Theranos had put its TSPU on a
  2602. 1:37:50Medevac helicopter?
  2603. 1:37:52No.
  2604. 1:37:54Why do you say no?
  2605. 1:37:57Because I No, I've never said that.
  2606. 1:37:59You never said that. Okay.
  2607. 1:38:00Um did you hear Sunny Balwani make this
  2608. 1:38:02statement to Fremont Group?
  2609. 1:38:04No.
  2610. 1:38:07Would the statement have been true in
  2611. 1:38:09late 2014?
  2612. 1:38:10No.
  2613. 1:38:21Did you tell Capital in October 2014
  2614. 1:38:25that Theranos
  2615. 1:38:27had an auditor
  2616. 1:38:28and that its financial statements were
  2617. 1:38:30audited as well?
  2618. 1:38:34Um I I don't know. I I know we were
  2619. 1:38:37discussing a new audit with them.
  2620. 1:38:40What do you recall about your
  2621. 1:38:41conversations regarding the new audit?
  2622. 1:38:44Um that we were discussing with them
  2623. 1:38:46engaging with KPMG to get an audit done.
  2624. 1:38:52Oh, in what context were they surprised
  2625. 1:38:54that
  2626. 1:38:55Theranos wasn't getting audits done?
  2627. 1:38:58No, I believe we were talking about
  2628. 1:39:01getting audits done on a go-forward
  2629. 1:39:02basis.
  2630. 1:39:05Did they ever ask to see audited
  2631. 1:39:07financials, historical financials?
  2632. 1:39:10I don't know.
  2633. 1:39:12They might have. I can't remember.
  2634. 1:39:20Did you ever tell Capital that KPMG was
  2635. 1:39:22Theranos's current auditor
  2636. 1:39:25in late 2014?
  2637. 1:39:27I don't know.
  2638. 1:39:28Did you hear Mr. Balwani make that
  2639. 1:39:30statement to Capital?
  2640. 1:39:32Just so I understand the question, what
  2641. 1:39:33do you mean by current auditor?
  2642. 1:39:35That KPMG had been hired by Theranos to
  2643. 1:39:37act as its auditor
  2644. 1:39:40as of late 2014.
  2645. 1:39:42Um we may have discussed it in terms of
  2646. 1:39:45the past years, but I know we discussed
  2647. 1:39:47with it we didn't have
  2648. 1:39:49um certain years audited.
  2649. 1:39:51Did you hear Mr. Balwani make that
  2650. 1:39:53statement to Capital that KPMG was
  2651. 1:39:55Theranos' current auditor as of late
  2652. 1:39:582014?
  2653. 1:39:59I'm not quite sure what current auditor
  2654. 1:40:01means, but no, I don't remember the
  2655. 1:40:02specifics of conversations.
  2656. 1:40:04Did Theranos have an auditor as of late
  2657. 1:40:072014?
  2658. 1:40:09Not for calendar year 2014, no.
  2659. 1:40:13Did you ever tell any
  2660. 1:40:14We were engaged with KPMG at that time
  2661. 1:40:16about auditing
  2662. 1:40:18uh recent years.
  2663. 1:40:20Did you ever tell any
  2664. 1:40:22with them. I'm sorry.
  2665. 1:40:23No, I apologize.
  2666. 1:40:24Good.
  2667. 1:40:25Does that cover it?
  2668. 1:40:26Yes.
  2669. 1:40:27No, no, I didn't
  2670. 1:40:27Sorry.
  2671. 1:40:28I was trying to be complete.
  2672. 1:40:29No, I appreciate it. The uh did you ever
  2673. 1:40:31tell any prospective investors that they
  2674. 1:40:34couldn't see Theranos' audited
  2675. 1:40:35financials because they revealed
  2676. 1:40:38commercially sensitive information about
  2677. 1:40:39the company?
  2678. 1:40:41Not that I can remember. I I believe
  2679. 1:40:44that was a discussion about how we would
  2680. 1:40:46share go-forward financials, but not
  2681. 1:40:49historical ones.
  2682. 1:40:51Uh what do you mean by that?
  2683. 1:40:53Um we were very focused in getting
  2684. 1:40:56audits.
  2685. 1:40:57It had we proceeded with getting audits
  2686. 1:40:59done at that time
  2687. 1:41:01uh about the disclosure of those
  2688. 1:41:03materials once they were complete
  2689. 1:41:05uh
  2690. 1:41:06with respect to how they handled
  2691. 1:41:07footnotes on the Walgreens and Safeway
  2692. 1:41:09contracts specifically.
  2693. 1:41:11So, you were anticipating sharing
  2694. 1:41:13audited financials with shareholders on
  2695. 1:41:15a go-forward basis?
  2696. 1:41:18I
  2697. 1:41:18I'm not sure exactly. I don't remember
  2698. 1:41:20the discussions very specifically, but I
  2699. 1:41:22I know that was an area of focus
  2700. 1:41:25uh when we were talking about starting
  2701. 1:41:26to get audited financials done at that
  2702. 1:41:28time.
  2703. 1:41:30Did the board ever encourage you to
  2704. 1:41:32get completed audited financials?
  2705. 1:41:34Not that I can remember.
  2706. 1:41:36Did you tell the board that Theranos had
  2707. 1:41:38not completed its
  2708. 1:41:39annual audits in sometime?
  2709. 1:41:41Yes.
  2710. 1:41:44Did you ever tell potential investors
  2711. 1:41:46that Theranos couldn't share audited
  2712. 1:41:48financials with them because it wasn't
  2713. 1:41:50sharing audited financials with other
  2714. 1:41:52investors?
  2715. 1:41:55Uh we generally disclosed that we didn't
  2716. 1:41:57have audited financials is my memory. Uh
  2717. 1:42:00I I again, if there's a specific
  2718. 1:42:01conversation, I could try to speak to it
  2719. 1:42:03more specifically.
  2720. 1:42:05Who do you recall having a conversation
  2721. 1:42:07with about the fact that Theranos had no
  2722. 1:42:09audited financials?
  2723. 1:42:11I I don't recall a specific
  2724. 1:42:12conversation. I just know we were very
  2725. 1:42:14open about it.
  2726. 1:42:17Did you ever tell Capital in late 2014
  2727. 1:42:20that there were no proximity uh Sorry,
  2728. 1:42:22let me start over again.
  2729. 1:42:24Did you ever tell Capital in late 2014
  2730. 1:42:26that there were no proximity limitations
  2731. 1:42:28in the Walgreens contract, just time
  2732. 1:42:31exclusivity?
  2733. 1:42:33I I don't know what that means.
  2734. 1:42:35Did you ever tell Capital that
  2735. 1:42:38um
  2736. 1:42:41that
  2737. 1:42:42uh
  2738. 1:42:43there were no geographic
  2739. 1:42:46limitations to the roll out of Theranos
  2740. 1:42:48services at Walgreens locations in late
  2741. 1:42:502014?
  2742. 1:42:52I'm sorry, just so I can answer your
  2743. 1:42:54question. What is a geographic
  2744. 1:42:55limitation?
  2745. 1:42:56That there was no that the company that
  2746. 1:42:58the two companies had not discussed any
  2747. 1:43:00limitations as to the roll out of
  2748. 1:43:03Theranos services in Walgreens stores in
  2749. 1:43:062015.
  2750. 1:43:08Sorry, Jessica, so I don't understand
  2751. 1:43:10what you're asking.
  2752. 1:43:12Okay, let me start over again.
  2753. 1:43:13Yeah.
  2754. 1:43:14Did you ever tell Capital that there
  2755. 1:43:16were no geographical limitations to
  2756. 1:43:18where Theranos could roll out its
  2757. 1:43:20services in Walgreens stores?
  2758. 1:43:24So
  2759. 1:43:25just making sure I'm answering the
  2760. 1:43:26question you're asking. The question is
  2761. 1:43:29that we could roll out anywhere in the
  2762. 1:43:31country?
  2763. 1:43:32Yes.
  2764. 1:43:33Um I don't remember specifically saying
  2765. 1:43:35that.
  2766. 1:43:36Did you ever hear Mr. Balwani making
  2767. 1:43:37that statement to Capital?
  2768. 1:43:40Not that I can remember.
  2769. 1:43:42Was that true as of
  2770. 1:43:44late 2014?
  2771. 1:43:46Was what true?
  2772. 1:43:47That statement.
  2773. 1:43:48Can you say one more time cuz none of us
  2774. 1:43:50we were all having a hard time so I want
  2775. 1:43:52to make sure she knows
  2776. 1:43:54what you're asking. What statement?
  2777. 1:43:56That there were no geographic
  2778. 1:43:57limitations to the roll out of Theranos
  2779. 1:43:59services in Walgreens stores. Did you
  2780. 1:44:01ever hear Mr. Balwani make that
  2781. 1:44:03statement
  2782. 1:44:04to Capital?
  2783. 1:44:05Not that I can recall.
  2784. 1:44:06Was that a true statement as of 2014?
  2785. 1:44:10I I don't really understand it um but
  2786. 1:44:14I mean again I know um I had access to
  2787. 1:44:16the Walgreens agreement.
  2788. 1:44:18And it was true that Theranos had to
  2789. 1:44:19work with Walgreens in order to decide
  2790. 1:44:21which additional stores to roll out
  2791. 1:44:23Theranos services in, correct?
  2792. 1:44:26I mean as as we've discussed today that
  2793. 1:44:29relationship evolved so much that I
  2794. 1:44:31don't know what the state of it was in
  2795. 1:44:33December '14 from memory.
  2796. 1:44:39It's true that Theranos couldn't
  2797. 1:44:40unilaterally decide to roll out in any
  2798. 1:44:43number of Walgreens stores without
  2799. 1:44:45Walgreens consent, correct?
  2800. 1:44:48Of course they had to work with us on
  2801. 1:44:49it.
  2802. 1:44:50Okay.
  2803. 1:44:53And you guys you understood that in
  2804. 1:44:54December 2014, is that correct?
  2805. 1:44:57Yes, they're stores. They would have to
  2806. 1:44:59be compliant with us
  2807. 1:45:01showing up in them.
  2808. 1:45:04Did you ever tell Capital in late 2014
  2809. 1:45:08that you were fairly confident on
  2810. 1:45:12hitting the 2014 financial projections?
  2811. 1:45:16I don't think so.
  2812. 1:45:17Did you ever hear Mr. Balwani make that
  2813. 1:45:19statement?
  2814. 1:45:20Not that I can remember.
  2815. 1:45:30Did you ever tell Capital in late 2014
  2816. 1:45:32that with respect to 2015 projections,
  2817. 1:45:35you believe that there could be a plus
  2818. 1:45:36or minus 30% variance due largely to
  2819. 1:45:40risk of execution?
  2820. 1:45:41I don't think so.
  2821. 1:45:42Did you ever hear Mr. Balwani make that
  2822. 1:45:44statement?
  2823. 1:45:44Not that I can remember.
  2824. 1:46:06You testified earlier that RDV
  2825. 1:46:08Corporation is the DeVos family,
  2826. 1:46:09correct?
  2827. 1:46:11Yes.
  2828. 1:46:12Who were your contacts at RDV
  2829. 1:46:14Corporation?
  2830. 1:46:16At what time?
  2831. 1:46:18Uh around the time that they were
  2832. 1:46:19considering to invest in Theranos.
  2833. 1:46:22Um I believe
  2834. 1:46:24Was it
  2835. 1:46:25Did you understand that he was part of
  2836. 1:46:26his team?
  2837. 1:46:28I don't know if I knew that at that
  2838. 1:46:30time. I met I think later.
  2839. 1:46:33And Theranos was having discussions with
  2840. 1:46:35RDV Corporation in uh late 2014 about
  2841. 1:46:38possibly investing in Theranos, correct?
  2842. 1:46:41Yes.
  2843. 1:46:43Did you tell RDV Corporation in late
  2844. 1:46:462014 that instead of vials of blood, one
  2845. 1:46:50for every test needed, that Theranos
  2846. 1:46:52required requires only a pinprick and a
  2847. 1:46:54drop of blood to perform hundreds of
  2848. 1:46:56tests?
  2849. 1:46:58I don't know.
  2850. 1:46:59Was that statement true as of late 2014?
  2851. 1:47:02Could you perform hundreds of tests on
  2852. 1:47:04one pin pinprick of blood?
  2853. 1:47:07We had developed hundreds of tests to
  2854. 1:47:10run on a pinprick of blood at that time.
  2855. 1:47:12It from a product development
  2856. 1:47:14standpoint.
  2857. 1:47:15So earlier we had talked about how it
  2858. 1:47:16was 70 tests on one pinprick of blood.
  2859. 1:47:19So now you're saying that a hundreds of
  2860. 1:47:21tests could be performed on one finger
  2861. 1:47:24prick
  2862. 1:47:25sample of blood.
  2863. 1:47:26Jesse, you just mischaracterized
  2864. 1:47:29one
  2865. 1:47:30you mischaracterized the earlier
  2866. 1:47:31testimony right now and what she just
  2867. 1:47:33said in response to your question.
  2868. 1:47:34They're two different questions. I mean
  2869. 1:47:35I
  2870. 1:47:37Elizabeth can answer but
  2871. 1:47:38I think you should ask the question
  2872. 1:47:39rather than suggest that she's saying
  2873. 1:47:41one thing now versus one thing earlier.
  2874. 1:47:43Well, can you square those two? That was
  2875. 1:47:45what I understood that you said. So, can
  2876. 1:47:46you square those two?
  2877. 1:47:48Which one is accurate?
  2878. 1:47:51So, are you assuming that only one can
  2879. 1:47:52be? That's not what I
  2880. 1:47:53Okay. So, if both of them are accurate,
  2881. 1:47:55how are they both accurate?
  2882. 1:47:56Yeah, I believe earlier today we were
  2883. 1:47:58talking about how from a product
  2884. 1:48:00development standpoint the
  2885. 1:48:03the novel chemistries that we developed
  2886. 1:48:05could work with a as low as a microliter
  2887. 1:48:07or less of blood.
  2888. 1:48:09And and therefore, if you you could run
  2889. 1:48:1170 of them for example from a single
  2890. 1:48:14sample.
  2891. 1:48:16Additionally, by this time fall of '14,
  2892. 1:48:20Theranos had created, developed, and had
  2893. 1:48:23development in what we thought were
  2894. 1:48:24validation reports for hundreds
  2895. 1:48:28of chemistries that we had actually made
  2896. 1:48:30the reagents for, made the chemistry
  2897. 1:48:32for, shown that the chemistry worked on
  2898. 1:48:34small sample volumes
  2899. 1:48:36from a product development standpoint.
  2900. 1:48:39So, so what your testimony is is that
  2901. 1:48:40the
  2902. 1:48:41the
  2903. 1:48:42if there's a reference to hundreds off
  2904. 1:48:44of a
  2905. 1:48:45off of a drop of blood,
  2906. 1:48:47it's
  2907. 1:48:49not 100 of tests with the same drop of
  2908. 1:48:51blood, but one drop
  2909. 1:48:53for each of those 100 tests
  2910. 1:48:55or or something like that.
  2911. 1:48:56my understanding of the statement that
  2912. 1:48:58you just
  2913. 1:48:59made.
  2914. 1:49:04Did you ever hear Mr. Balwani make the
  2915. 1:49:06statement that Theranos required is only
  2916. 1:49:08a pin prick and a drop of blood to
  2917. 1:49:10perform hundreds of tests?
  2918. 1:49:13I I don't know.
  2919. 1:49:21Did you
  2920. 1:49:22tell RDB Corporation in late 2014 that
  2921. 1:49:26Theranos' revenue for 2015 is projected
  2922. 1:49:29to be $990 million?
  2923. 1:49:32I don't think so.
  2924. 1:49:33Did you ever hear Mr. Balwani make that
  2925. 1:49:35statement?
  2926. 1:49:36Not that I can remember.
  2927. 1:49:39Did you ever tell RDB Corporation that
  2928. 1:49:43Theranos would open
  2929. 1:49:46or or was on the path to opening 900
  2930. 1:49:48Walgreens Theranos centers by 2015?
  2931. 1:49:51I don't think so.
  2932. 1:49:52Did you ever hear Mr. Balwani make that
  2933. 1:49:55statement?
  2934. 1:49:56Not that I can remember.
  2935. 1:49:58Did you ever tell RDB Corporation that
  2936. 1:50:00Theranos has no debt
  2937. 1:50:02and has no plans to take on any debt
  2938. 1:50:04financing?
  2939. 1:50:05I don't think so.
  2940. 1:50:06Did you ever hear Mr. Balwani make that
  2941. 1:50:08statement?
  2942. 1:50:08Not that I can remember.
  2943. 1:50:10Was that statement true as of late 2014?
  2944. 1:50:13I think so.
  2945. 1:50:14Did you consider
  2946. 1:50:16uh the Walgreens convertible note and
  2947. 1:50:18the Safeway convertible note as debt?
  2948. 1:50:22I I don't know.
  2949. 1:50:24What did you consider that as?
  2950. 1:50:27Not debt.
  2951. 1:50:28I I'm not sure. I don't know.
  2952. 1:50:30Was there interest that Theranos was
  2953. 1:50:32paying on that loan those two loans?
  2954. 1:50:36At that time I I don't know if we were
  2955. 1:50:38thinking that that loan was going to
  2956. 1:50:40convert into equity. I'm not sure how we
  2957. 1:50:42were thinking about it.
  2958. 1:50:46So, it's been a little over an hour. Can
  2959. 1:50:47we take a break?
  2960. 1:50:49Or are you going to be here?
  2961. 1:50:50You know, I'm still in the middle of
  2962. 1:50:50this document, so I only have a few more
  2963. 1:50:52questions and then we can take a break.
  2964. 1:50:54Okay.
  2965. 1:50:55Apart from the end of the day.
  2966. 1:50:57I have three more questions.
  2967. 1:50:58Not from the totally from the end.
  2968. 1:51:00No, no, no.
  2969. 1:51:00For the for the day.
  2970. 1:51:01Why don't we talk about that at the
  2971. 1:51:02break and I think there's just a couple
  2972. 1:51:04more questions on this kind of theme and
  2973. 1:51:05then we can
  2974. 1:51:07Did you ever tell RDB Corporation in
  2975. 1:51:09late 2014 that cash you would raise from
  2976. 1:51:12them would be used to redeem earlier
  2977. 1:51:14investors with shorter term investment
  2978. 1:51:16horizons.
  2979. 1:51:17Could you read that again?
  2980. 1:51:19Did you ever tell capital that
  2981. 1:51:22Sorry, RDD?
  2982. 1:51:23I'm sorry. Did you ever tell RDD
  2983. 1:51:24corporation in late 2014 that cash you
  2984. 1:51:28were going to raise
  2985. 1:51:30from them and other investors would be
  2986. 1:51:32used to redeem earlier investors with
  2987. 1:51:34shorter term investment horizons?
  2988. 1:51:37I don't know if I said that, but that
  2989. 1:51:38was definitely one of the strategies for
  2990. 1:51:41raising money from long-term family sort
  2991. 1:51:43of controlled companies and investment
  2992. 1:51:46entities.
  2993. 1:51:47Did you ever hear Mr. Balwani make that
  2994. 1:51:48statement?
  2995. 1:51:49I don't know.
  2996. 1:51:53Did Theranos ever redeem earlier
  2997. 1:51:54investors with the C2 proceeds?
  2998. 1:51:58Not in the way we had wanted to, which
  2999. 1:52:00was
  3000. 1:52:02sort of
  3001. 1:52:03buy out um
  3002. 1:52:06certain entities that we had learned did
  3003. 1:52:09not have sort of a long-term interest in
  3004. 1:52:10holding the shares. Um we we did a
  3005. 1:52:12little bit of exercising the right of
  3006. 1:52:15first refusal to make sure that shares
  3007. 1:52:18didn't end up in secondary markets.
  3008. 1:52:20I guess what why didn't Theranos uh sort
  3009. 1:52:23of pursue that
  3010. 1:52:25uh shareholder consolidation strategy
  3011. 1:52:27more aggressively?
  3012. 1:52:29Because shortly after we closed this
  3013. 1:52:31round, we started dealing with the Wall
  3014. 1:52:32Street Journal and then very shortly
  3015. 1:52:34after that we're
  3016. 1:52:36in
  3017. 1:52:38sort of crisis mode trying to deal with
  3018. 1:52:40the issues with the Journal and then
  3019. 1:52:41regulators.
  3020. 1:52:42Is it just general timing?
  3021. 1:52:45Yes, we we didn't get the chance to
  3022. 1:52:47execute on the plan we had.
  3023. 1:52:50Did you tell RDD corporation in late
  3024. 1:52:522014 that Theranos uses its own analyzer
  3025. 1:52:55equipment?
  3026. 1:52:58I I don't know if I did. I'm
  3027. 1:53:00I'm I'm not sure.
  3028. 1:53:01Did you ever hear Mr. Balwani make that
  3029. 1:53:03statement?
  3030. 1:53:04Uh again, I can't remember the specifics
  3031. 1:53:06of these conversations. don't, I don't
  3032. 1:53:07know.
  3033. 1:53:09Did you ever tell RDV Corporation in
  3034. 1:53:12late 2014 that the Theranos analyzer
  3035. 1:53:15is a small fraction of the size of a
  3036. 1:53:17current lab?
  3037. 1:53:20I can't remember the specifics of the
  3038. 1:53:22conversation, but
  3039. 1:53:24that's reflective of mini lab.
  3040. 1:53:27Did you ever hear Mr. Balwani make that
  3041. 1:53:28statement to um sorry, to RDV Corp
  3042. 1:53:30Corporation?
  3043. 1:53:31I I don't know.
  3044. 1:53:35Okay.
  3045. 1:53:36Okay, we can take a break. We are off
  3046. 1:53:37the record at 3:34.

About this transcript

This page contains the full transcript of Elizabeth Holmes SEC Deposition AUG 23, 2017 3 OF 4 redacted by ANTL Media, generated from the public captions YouTube serves with the video. The transcript has 16,073 words across 3,046 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.

What you can do with it

Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.

Free YouTube transcript tool

YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.